Metrikler
Yayın
384
Açık Erişim
28
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
1995 - 2000
1995 - 2000Tıpta Uzmanlık
Karadeniz Teknik Üniversitesi, Nöroloji, Türkiye
1988 - 1994
1988 - 1994Lisans
Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Türkiye
Yabancı Diller
B2 Orta Üstü
B2 Orta Üstüİngilizce
B1 Orta
B1 OrtaFransızca
Araştırma Alanları
Tıp
Sağlık Bilimleri
Dahili Tıp Bilimleri
Nöroloji
Akademik Ünvanlar / Görevler
2000 - Devam Ediyor
2000 - Devam EdiyorProf. Dr.
Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Dahili Tıp
Akademi Dışı Deneyim
2014 - Devam Ediyor
2014 - Devam EdiyorSayman, Yönetim kurulu üyesi
Türk Nöroloji Dermeği, Sayman, Yönetim kurulu üyesi
2011 - 2011
2011 - 2011Clinical Fellow
University of British Columbia, MS Clinic, Vancouver, Clinical Fellow
2005 - 2005
2005 - 2005Clinical Fellow
University of British Columbia, MS Clinic, Vancouver, Clinical Fellow
Makaleler
Tümü (189)
SCI-E, SSCI, AHCI (154)
SCI-E, SSCI, AHCI, ESCI (165)
ESCI (12)
Scopus (173)
TRDizin (29)
Diğer Yayınlar (5)
2025
20251. Exome sequencing reveals low-frequency and rare variant contributions to multiple sclerosis susceptibility in Turkish families
Büyükgöl F., GÜRDAMAR B., Aluçlu M. U., Beckmann Y., BİLGÜVAR K., BOZ C., et al.
Scientific Reports
, cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)
2025
20252. Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data
Pirmani A., De Brouwer E., Arany Á., Oldenhof M., Passemiers A., Faes A., et al.
npj Digital Medicine
, cilt.8, sa.1, 2025 (SCI-Expanded, Scopus)
2025
20253. Disease course after pregnancy in women with progressive multiple sclerosis symptoms
Shipley J., Beadnall H. N., Sanfilippo P. G., Horakova D., BOZ C., Prat A., et al.
Multiple Sclerosis Journal
, cilt.31, sa.12, ss.1439-1451, 2025 (SCI-Expanded, Scopus)
2025
20254. Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)
Jokubaitis V. G., Alroughani R., Altintas A., Eichau S., Hughes S., Willekens B., et al.
Multiple Sclerosis Journal
, cilt.31, sa.9, ss.1088-1101, 2025 (SCI-Expanded, Scopus)
2025
20255. Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study
Siriratnam P., Huda S., Van der Walt A., Sanfilippo P., Sharmin S., Foong Y. C., et al.
Journal of neurology
, cilt.272, sa.5, ss.339, 2025 (SCI-Expanded, Scopus)
2025
20256. Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis
Foong Y. C., Merlo D., Gresle M., Buzzard K., Horakova D., Havrdova E. K., et al.
Journal of Neurology, Neurosurgery and Psychiatry
, 2025 (SCI-Expanded, Scopus)
2025
20257. Persistent progression independent of relapse activity in multiple sclerosis
Zhu C., Zhou Z., Kalincik T., Roos I., Buzzard K., Skibina O., et al.
Brain Communications
, cilt.7, sa.5, 2025 (ESCI, Scopus)
2024
20248. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study
Dekeyser C., Hautekeete M., Cambron M., Van Pesch V., Patti F., Kuhle J., et al.
Journal of Neurology, Neurosurgery and Psychiatry
, sa.11, ss.1021-1031, 2024 (SCI-Expanded, Scopus)
2024
20249. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies
Yeh W. Z., van der Walt A., Skibina O. G., Kalincik T., Alroughani R., Kermode A. G., et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
, cilt.11, sa.6, 2024 (SCI-Expanded, Scopus)
2024
202410. Determination of important predictors for the fifth-year Expanded Disability Status Scale scores of patients with multiple sclerosis using machine learning
Buçan Kırkbir İ., Kurt B., Boz C., Terzi M.
Turkish Journal of Neurology
, cilt.30, sa.3, ss.157-166, 2024 (ESCI, Scopus, TRDizin)
2024
202411. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Roos I., Sharmin S., Malpas C., Ozakbas S., Lechner-Scott J., Hodgkinson S., et al.
Multiple Sclerosis Journal
, cilt.30, sa.9, ss.1163-1175, 2024 (SCI-Expanded, Scopus)
2024
202412. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60
Foong Y. C., Merlo D., Gresle M., Buzzard K., Zhong M., Yeh W. Z., et al.
Journal of Neurology, Neurosurgery and Psychiatry
, cilt.95, sa.8, ss.767-774, 2024 (SCI-Expanded, Scopus)
2024
202413. Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein
KOÇ S., ŞEN S., TERZİ Y., KIZILAY F., DEMİR S., AKSOY D. B., et al.
Balkan Medical Journal
, cilt.41, sa.4, ss.272-279, 2024 (SCI-Expanded, Scopus, TRDizin)
2023
202314. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Kubala Havrdova E., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
, cilt.94, sa.12, ss.1004-1011, 2023 (SCI-Expanded, Scopus)
2023
202315. Risk of secondary progressive multiple sclerosis after early worsening of disability
Dzau W., Sharmin S., Patti F., Izquierdo G., Eichau S., Prat A., et al.
Journal of Neurology, Neurosurgery and Psychiatry
, cilt.94, sa.12, ss.984-991, 2023 (SCI-Expanded, Scopus)
2023
202316. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Sharmin S., Roos I., Simpson-Yap S., Malpas C., Sánchez M. M., Ozakbas S., et al.
Brain : a journal of neurology
, cilt.146, sa.11, ss.4633-4644, 2023 (SCI-Expanded, Scopus)
2023
202317. Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting
Altunan B., Ünal A., EFENDİ H., Köseoğlu M., Terzi M., Kotan D., et al.
Multiple Sclerosis and Related Disorders
, cilt.77, 2023 (SCI-Expanded, Scopus)
2023
202318. Disability accrual in primary and secondary progressive multiple sclerosis
Harding-Forrester S., Roos I., Nguyen A., Malpas C. B., Diouf I., Moradi N., et al.
Journal of Neurology, Neurosurgery and Psychiatry
, cilt.94, sa.9, ss.707-717, 2023 (SCI-Expanded, Scopus)
2023
202319. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
Tütüncü M., Demir S., Arslan G., Dinç Ö., Şen S., GÜNDÜZ T., et al.
Multiple Sclerosis and Related Disorders
, cilt.75, 2023 (SCI-Expanded, Scopus)
2023
202320. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
BOZ C., ÖZAKBAŞ S., Terzi M., KARABUDAK R., Sevim S., Turkoglu R., et al.
Neurological Sciences
, cilt.44, sa.6, ss.2121-2129, 2023 (SCI-Expanded, Scopus)
2023
202321. Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment
Terzi M., Helvaci E. M., Şen S., BOZ C., Çilingir V., Akçali A., et al.
Noropsikiyatri Arsivi
, cilt.60, sa.1, ss.23-27, 2023 (SCI-Expanded, Scopus, TRDizin)
2023
202322. External validation of a clinical prediction model in multiple sclerosis
Moradi N., Sharmin S., Malpas C. B., Shaygannejad V., Terzi M., BOZ C., et al.
Multiple Sclerosis Journal
, cilt.29, sa.2, ss.261-269, 2023 (SCI-Expanded, Scopus)
2023
202323. Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)
Tuncer A., Kürtüncü M., Terzi M., UYGUNOĞLU U., Göncüoğlu C., Yüceyar A. N., et al.
Turkish Journal of Medical Sciences
, cilt.53, sa.1, ss.323-332, 2023 (SCI-Expanded, Scopus, TRDizin)
2023
202324. The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVİD-19 in Multiple Sclerosis
Şen S., Arslan G., Tütüncü M., Demir S., Dinç Ö., GÜNDÜZ T., et al.
Noropsikiyatri Arsivi
, cilt.60, sa.3, ss.252-256, 2023 (SCI-Expanded, Scopus, TRDizin)
2023
202325. Clinical course and outcome of Covid-19 in patients with myasthenia gravis
Aktoz G., BOZ C., Zengin S., Okumus A. C., Horozoglu H., KARA F., et al.
Neurological Research
, cilt.45, sa.6, ss.583-589, 2023 (SCI-Expanded, Scopus)
2023
202326. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis
Usta N. C., BOZ C., Terzi M.
Clinical Neurology and Neurosurgery
, cilt.224, 2023 (SCI-Expanded, Scopus)
2022
202227. Evaluation of clinical features and prognosis of myasthenia gravis in adults based on the age of onset: A retrospective study from a single center of 30 years MG registry
KARA F., GÖL M. F., BOZ C.
Neurology Asia
, cilt.27, sa.4, ss.981-989, 2022 (SCI-Expanded, Scopus)
2022
202228. Updated Results of the COVID-19 in MS Global Data Sharing Initiative Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity
Simpson-Yap S., Pirmani A., Kalincik T., De Brouwer E., Geys L., Parciak T., et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
, cilt.9, sa.6, 2022 (SCI-Expanded, Scopus)
2022
202229. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
Zhu C., Zhou Z., Roos I., Merlo D., Kalincik T., ÖZAKBAŞ S., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
, cilt.93, ss.1330-1337, 2022 (SCI-Expanded, Scopus)
2022
202230. Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
Simpson-Yap S., Pirmani A., De Brouwer E., Peeters L. M., Geys L., Parciak T., et al.
Multiple Sclerosis and Related Disorders
, cilt.66, 2022 (SCI-Expanded, Scopus)
2022
202231. Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS
Kalincik T., Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.28, sa.11, ss.1752-1761, 2022 (SCI-Expanded, Scopus)
2022
202232. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., et al.
NEUROLOGY
, cilt.99, sa.17, 2022 (SCI-Expanded, Scopus)
2022
202233. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry
Sharmin S., Malpas C. B., Roos I., Diouf I., Alroughani R., ÖZAKBAŞ S., et al.
Journal of Neurology, Neurosurgery and Psychiatry
, cilt.93, sa.12, ss.1322-1329, 2022 (SCI-Expanded, Scopus)
2022
202234. Confirmed disability progression as a marker of permanent disability in multiple sclerosis
Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., et al.
EUROPEAN JOURNAL OF NEUROLOGY
, cilt.29, sa.8, ss.2321-2334, 2022 (SCI-Expanded, Scopus)
2022
202235. Disease activity during pregnancy and postpartum in women with MS receiving ocrelizumab in a real-world cohort
Yeh W., Van der Walt A., Kermode A., Kalincik T., Alroughani R., Lechner-Scott J., et al.
EUROPEAN JOURNAL OF NEUROLOGY
, cilt.29, ss.295-296, 2022 (SCI-Expanded, Scopus)
2022
202236. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study
Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al.
NEUROLOGY
, cilt.98, sa.24, 2022 (SCI-Expanded, Scopus)
2022
202237. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Lefort M., Sharmin S., Andersen J. B., Vukusic S., Casey R., Debouverie M., et al.
BMC MEDICAL RESEARCH METHODOLOGY
, cilt.22, sa.1, 2022 (SCI-Expanded, Scopus)
2022
202238. Prediction of multiple sclerosis outcomes when switching to ocrelizumab
Zhong M., van der Walt A., Stankovich J., Kalincik T., Buzzard K., Skibina O., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.28, sa.6, ss.958-969, 2022 (SCI-Expanded, Scopus)
2022
202239. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
Herring W. L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., et al.
PharmacoEconomics
, cilt.40, sa.3, ss.323-339, 2022 (SCI-Expanded, SSCI, Scopus)
2022
202240. Neurological manifestations and etiological risk factors in patients hospitalized with COVID-19 in Turkey
Usta N. C., Kartal S., Gunay B. O., BOZ C.
Asian Biomedicine
, cilt.16, sa.1, ss.23-30, 2022 (SCI-Expanded, Scopus)
2022
202241. Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression
Sevim S., DEMİRKIRAN D. M., Terzi M., YÜCEYAR A. N., Tasdelen B., Idiman E., et al.
ARQUIVOS DE NEURO-PSIQUIATRIA
, cilt.80, ss.168-172, 2022 (SCI-Expanded, Scopus)
2022
202242. EFFECTS OF RITUXIMAB ON PROGNOSIS IN MYASTHENIA GRAVIS: A SINGLE-CENTER EXPERIENCE FROM TURKEY
GÖL M. F., KARA F., BOZ M., MUTLU A., Karakullukçu S., BOZ C.
Ideggyogyaszati Szemle
, cilt.75, sa.9-10, ss.351-359, 2022 (SCI-Expanded, Scopus)
2021
202143. Neuropathic Pain Frequency in Neurology Outpatients: A Multicenter Study
Bekircan-Kurt C. E., Inan B., Bulut O., Sengun I., KARLI H. N., Gunes N., et al.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
, cilt.58, sa.4, ss.257-260, 2021 (SCI-Expanded, Scopus, TRDizin)
2021
202144. A Case Report of Acute Disseminated Encephalomyelitis in a Pregnant Woman After COVID-19 Infection
KIZILIRMAK R., ÖZALP M., OSMANAĞAOĞLU M. A., BOZ C.
TURK NOROLOJI DERGISI
, cilt.27, ss.49-51, 2021 (ESCI, Scopus, TRDizin)
2021
202145. Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry
Kenney R., Liu M., Patil S., Alroughani R., Ampapa R., Bergamaschi R., et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES
, cilt.430, 2021 (SCI-Expanded, Scopus)
2021
202146. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E. K., et al.
CNS DRUGS
, cilt.35, sa.11, ss.1217-1232, 2021 (SCI-Expanded, Scopus)
2021
202147. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018
Moradi N., Sharmin S., Malpas C., ÖZAKBAŞ S., Shaygannejad V., Terzi M., et al.
CNS DRUGS
, cilt.35, sa.10, ss.1097-1106, 2021 (SCI-Expanded, Scopus)
2021
202148. Determinants of therapeutic lag in multiple sclerosis
Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.12, ss.1838-1851, 2021 (SCI-Expanded, Scopus)
2021
202149. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
De Brouwer E., Becker T., Moreau Y., Havrdova E. K., Trojano M., Eichau S., et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
, cilt.208, 2021 (SCI-Expanded, Scopus)
2021
202150. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies
Andersen J. B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., Sorensen P. S., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
, cilt.53, 2021 (SCI-Expanded, Scopus)
2021
202151. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Yeh W. Z., Widyastuti P. A., Van der Walt A., Stankovich J., Havrdova E., Horakova D., et al.
NEUROLOGY
, cilt.96, sa.24, 2021 (SCI-Expanded, Scopus)
2021
202152. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis
Minh Le M. L., Malpas C., Sharmin S., Horakova D., Havrdova E., Trojano M., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.5, ss.755-766, 2021 (SCI-Expanded, Scopus)
2021
202153. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score
Kunchok A., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.27, sa.5, ss.695-705, 2021 (SCI-Expanded, Scopus)
2021
202154. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
Kalincik T., Diouf I., Sharmin S., Malpas C., Spelman T., Horakova D., et al.
NEUROLOGY
, cilt.96, sa.5, 2021 (SCI-Expanded, Scopus)
2021
202155. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., et al.
NEUROLOGY
, cilt.96, sa.2, 2021 (SCI-Expanded, Scopus)
2021
202156. Determinants of disability development in patients with multiple sclerosis
KARA F., GÖL M. F., BOZ C.
ARQUIVOS DE NEURO-PSIQUIATRIA
, cilt.79, sa.6, ss.489-496, 2021 (SCI-Expanded, Scopus)
2021
202157. The Role of Thrombo-inflammatory Biomarkers in the Prognosis of Cere-bral Venous Sinus Thrombosis
Karahan S. Z., GAZİOĞLU S., DİLAVER İ., BOZ C.
CURRENT NEUROVASCULAR RESEARCH
, cilt.18, sa.2, ss.237-243, 2021 (SCI-Expanded, Scopus)
2021
202158. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study
Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.
NEUROIMAGE-CLINICAL
, cilt.32, 2021 (SCI-Expanded, Scopus)
2021
202159. Genotype phenotype correlation of cadasil patients-single center experience
ÇEBİ A. H., BOZ C.
Annals of Medical Research
, cilt.28, sa.02, ss.381-384, 2021 (TRDizin)
2020
202060. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis
Lizak N., Malpas C. B., Sharmin S., Havrdova E. K., Horakova D., Izquierdo G., et al.
JAMA NEUROLOGY
, cilt.77, sa.11, ss.1398-1407, 2020 (SCI-Expanded, Scopus)
2020
202061. Methylprednisolone Concentrations in Breast Milk and Serum of Patients with Multiple Sclerosis Treated with IV Pulse Methylprednisolone
Karahan S. Z., BOZ C., Terzi M., Aktoz G., Sen S., Ozbudun B., et al.
CLINICAL NEUROLOGY AND NEUROSURGERY
, cilt.197, 2020 (SCI-Expanded, Scopus)
2020
202062. Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.
BRAIN
, cilt.143, ss.2742-2756, 2020 (SCI-Expanded, Scopus)
2020
202063. Revisiting the complex architecture of ALS in Turkey: Expanding genotypes, shared phenotypes, molecular networks, and a public variant database
Tunca C., Seker T., Akcimen F., Coskun C., Bayraktar E., Palvadeau R., et al.
HUMAN MUTATION
, cilt.41, sa.8, 2020 (SCI-Expanded, Scopus)
2020
202064. 'Is RLS a harbinger and consequence of MS?: Striking results of the 'RELOMS-T' study'
Sevim S., DEMİRKIRAN D. M., Terzi M., YÜCEYAR A. N., Tasdelen B., Idiman E., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
, cilt.42, 2020 (SCI-Expanded, Scopus)
2020
202065. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review
AlSharoqi I. A., Aljumah M., Bohlega S., BOZ C., Daif A., El-Koussa S., et al.
NEUROLOGY AND THERAPY
, cilt.9, sa.1, ss.55-66, 2020 (SCI-Expanded, ESCI, Scopus)
2020
202066. The COVID-19 from Neurological Overview
ACAR T., ACIMAN DEMİREL E., AFŞAR FAK N. E. Y., AKÇALI A., AKMAN DEMİR G., ALAGÖZ A. N., et al.
Turkish Journal Of Neurology
, cilt.26, sa.2, ss.58-108, 2020 (ESCI, Scopus, TRDizin)
2020
202067. Nöro-Behçet Hastalığında Klinik Özellikler
Gazioğlu S., Boz M., Aksu Arıca D., Boz C.
Dicle Tıp Dergisi , cilt.47, sa.2, ss.324-330, 2020 (TRDizin)
2020
202068. Early clinical markers of aggressive multiple sclerosis
Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.
BRAIN
, cilt.143, ss.1400-1413, 2020 (SCI-Expanded, Scopus)
2020
202069. Decreased second to fourth digit ratios in female multiple sclerosis patients
GAZİOĞLU S., ALKAN İ., KARAMAN A. G., BOZ C.
EARLY HUMAN DEVELOPMENT
, cilt.144, 2020 (SCI-Expanded, Scopus)
2020
202070. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder
Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., TERZİ M., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
, cilt.38, 2020 (SCI-Expanded, Scopus)
2020
202071. Electrophysiological, functional and histopathological assessments of high dose melatonin on regeneration after blunt sciatic nerve injury
Yazar U., Çakır E., Boz C., Çobanoğlu Ü., Baykal S.
JOURNAL OF CLINICAL NEUROSCIENCE
, cilt.72, ss.370-377, 2020 (SCI-Expanded, Scopus)
2020
202072. Risk of secondary progressive multiple sclerosis: A longitudinal study
Fambiatos A., Jokubaitis V., Horakova D., Havrdova E. K., Trojano M., Prat A., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.26, sa.1, ss.79-90, 2020 (SCI-Expanded, Scopus)
2019
201973. A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial
Akman Demir G., Turkoglu R., Saip S., Yuceyar N., EFENDİ H., TURAN Ö. F., et al.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
, cilt.56, sa.4, ss.253-257, 2019 (SCI-Expanded, Scopus, TRDizin)
2019
201974. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis
BOZ C., TERZİ M., Ozer B., Turkoglu R., KARABUDAK R., EFENDİ H., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
, cilt.36, 2019 (SCI-Expanded, Scopus)
2019
201975. International consensus on quality standards for brain health-focused care in multiple sclerosis
Hobart J., Bowen A., Pepper G., Crofts H., Eberhard L., Berger T., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.25, sa.13, ss.1809-1818, 2019 (SCI-Expanded, Scopus)
2019
201976. The Efficacy of Acupuncture in the Treatment of Bell's Palsy Sequelae
Ertemoğlu Öksüz C., Kalaycioglu A., Uzun Ö., Kalkışım Ş. N., Zihni N. B., Yildirim A., et al.
JOURNAL OF ACUPUNCTURE AND MERIDIAN STUDIES
, cilt.12, sa.4, ss.122-130, 2019 (ESCI, Scopus)
2019
201977. Susac Syndrome: Clinical characteristics, diagnostic findings and treatment in 19 cases
Karahan S. Z., Boz C., Saip S., Kale N., Demirkaya S., Celik Y., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
, cilt.33, ss.94-99, 2019 (SCI-Expanded, Scopus)
2019
201978. The efficacy of acupuncture in the treatment of Bell’xxs palsy sequelae
ERTEMOĞLU ÖKSÜZ C., KALAYCIOĞLU A., UZUN Ö., KALKIŞIM Ş. N., ZİHNİ N. B., Yıldırım A., et al.
JOURNAL OF ACUPUNCTURE AND MERIDIAN STUDIES , 2019 (Scopus)
2019
201979. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Kalincik T., Havrdova E. K., Horakova D., Izquierdo G., Prat A., Girard M., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
, cilt.90, sa.4, ss.458-468, 2019 (SCI-Expanded, Scopus)
2019
201980. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
Nguyen A., Havrdova E. K., Horakova D., Izquierdo G., Kalincik T., van der Walt A., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
, cilt.28, ss.235-243, 2019 (SCI-Expanded, Scopus)
2019
201981. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
Brown J. W. L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
, cilt.321, sa.2, ss.175-187, 2019 (SCI-Expanded, Scopus)
2019
201982. Clinical and morphometric examination of acupuncture effect in Bell's palsy sequelae
Oksuz C., Kalaycioglu A., Yildirim A., Uzun Ö., Kalkışım Ş. N., Zihni N. B., et al.
CUKUROVA MEDICAL JOURNAL
, cilt.44, ss.11-19, 2019 (ESCI, TRDizin)
2019
201983. Pediatrik Yaş Başlangıçlı Multipl Skleroz ile Erişkin Yaş Başlangıçlı Multipl Sklerozun Karşılaştırılması
DİLBER B., DİLER DURGUT B., ACAR ARSLAN E., ŞAHİN S., CANSU A., BOZ C., et al.
TURKİYE KLİNİKLERİ JOURNAL OF NEUROLOGY , 2019 (TRDizin)
2019
201984. A rare metabolic disease: cerebrotendinous xanthomatosis
Kamaşak T., Demirhan Y. N., Parıltan Küçükalioğlu B., Boz C., Çebi A. H., Eyüboğlu İ., et al.
Van Medical Journal
, cilt.26, sa.2, ss.265-267, 2019 (TRDizin)
2018
201885. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
Hughes J., Jokubaitis V., Lugaresi A., Hupperts R., Izquierdo G., Prat A., et al.
JAMA NEUROLOGY
, cilt.75, sa.11, ss.1407-1415, 2018 (SCI-Expanded, Scopus)
2018
201886. Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis
Min M., Spelman T., Lugaresi A., BOZ C., Spitaleri D. L. A., Pucci E., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.24, sa.12, ss.1569-1577, 2018 (SCI-Expanded, Scopus)
2018
201887. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy
Kister I., Spelman T., Patti F., Duquette P., Trojano M., Izquierdo G., et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES
, cilt.391, ss.72-76, 2018 (SCI-Expanded, Scopus)
2018
201888. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis
BOZ C., TERZİ M., Karahan S. Z., Sen S., Sarac Y., Mavis M. E.
MULTIPLE SCLEROSIS JOURNAL
, cilt.24, sa.9, ss.1205-1211, 2018 (SCI-Expanded, Scopus)
2018
201889. Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]
Fragoso Y. D., Brooks J. B. B., Spelman T., BOZ C., Alroughani R., Lugaresi A., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
, cilt.22, ss.166, 2018 (SCI-Expanded, Scopus)
2018
201890. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis
Signori A., Izquierdo G., Lugaresi A., Hupperts R., Grand'Maison F., Sola P., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.24, sa.5, ss.642-652, 2018 (SCI-Expanded, Scopus)
2018
201891. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Kappos L., Bar-Or A., Cree B. A. C., Fox R. J., Giovannoni G., Gold R., et al.
The Lancet
, cilt.391, sa.10127, ss.1263-1273, 2018 (SCI-Expanded, Scopus)
2018
201892. Pregnancy-induced Susac Syndrome: A Case Report
Usta N. C., BOZ C., Ozmenoglu M.
TURKISH JOURNAL OF NEUROLOGY
, cilt.24, sa.1, ss.70-71, 2018 (ESCI, Scopus, TRDizin)
2018
201893. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod
Fragoso Y. D., Spelman T., BOZ C., Alroughani R., Lugaresi A., Vucic S., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
, cilt.19, ss.105-108, 2018 (SCI-Expanded, Scopus)
2017
201794. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
Howard J. F., Utsugisawa K., Benatar M., Murai H., Barohn R. J., Illa I., et al.
LANCET NEUROLOGY
, cilt.16, sa.12, ss.976-986, 2017 (SCI-Expanded)
2017
201795. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Lorscheider J., Jokubaitis V. G., Spelman T., Izquierdo G., Lugaresi A., Havrdova E., et al.
NEUROLOGY
, cilt.89, sa.10, ss.1050-1059, 2017 (SCI-Expanded, Scopus)
2017
201796. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
Kalincik T., Manouchehrinia A., Sobisek L., Jokubaitis V., Spelman T., Horakova D., et al.
BRAIN
, cilt.140, ss.2426-2443, 2017 (SCI-Expanded, Scopus)
2017
201797. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice
Spelman T., Meyniel C., Ignacio Rojas J., Lugaresi A., Izquierdo G., Grand'Maison F., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.23, sa.10, ss.1346-1357, 2017 (SCI-Expanded, Scopus)
2017
201798. Prognostic Indicators in Pediatric Clinically Isolated Syndrome
Iaffaldano P., Simone M., Lucisano G., Ghezzi A., Coniglio G., Morra V. B., et al.
ANNALS OF NEUROLOGY
, cilt.81, sa.5, ss.729-739, 2017 (SCI-Expanded, Scopus)
2017
201799. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Kalincik T., Brown J. W. L., Robertson N., Willis M., Scolding N., Rice C. M., et al.
LANCET NEUROLOGY
, cilt.16, sa.4, ss.271-281, 2017 (SCI-Expanded, Scopus)
2017
2017100. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
Lizak N., Lugaresi A., Alroughani R., Lechner-Scott J., Slee M., Havrdova E., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
, cilt.88, sa.3, ss.196-203, 2017 (SCI-Expanded, Scopus)
2017
2017101. Contribution of different relapse phenotypes to disability in multiple sclerosis
Stewart T., Spelman T., Havrdova E., Horakova D., Trojano M., Izquierdo G., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.23, sa.2, ss.266-276, 2017 (SCI-Expanded, Scopus)
2017
2017102. A Comparison of Pediatric- and Adult-Onset Multiple Sclerosis
KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., et al.
Turkiye Klinikleri Journal of Neurology
, cilt.12, sa.3, ss.57-63, 2017 (TRDizin)
2017
2017103. Pediatrik Yaş Başlangıçlı Multipl Skleroz ileErişkin Yaş Başlangıçlı Multipl SklerozunKarşılaştırılmasıA Comparison of Pediatric- and Adult-Onset Multiple Sclerosis
KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., et al.
Turkiye Klinikleri Journal of Neurology , cilt.12, sa.3, ss.57-63, 2017 (TRDizin)
2016
2016104. Defining secondary progressive multiple sclerosis
Lorscheider J., Buzzard K., Jokubaitis V., Spelman T., Havrdova E., Horakova D., et al.
BRAIN
, cilt.139, ss.2395-2405, 2016 (SCI-Expanded, Scopus)
2016
2016105. Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis
Jokubaitis V. G., Spelman T., Kalincik T., Lorscheider J., Havrdova E., Horakova D., et al.
ANNALS OF NEUROLOGY
, cilt.80, sa.1, ss.89-100, 2016 (SCI-Expanded, Scopus)
2016
2016106. Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS
Spelman T., Kalincik T., Jokubaitis V., Zhang A., Pellegrini F., Wiendl H., et al.
NEUROLOGY-CLINICAL PRACTICE
, cilt.6, sa.2, ss.102-115, 2016 (ESCI, Scopus)
2016
2016107. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Warrender-Sparkes M., Spelman T., Izquierdo G., Trojano M., Lugaresi A., Grand'Maison F., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.22, sa.4, ss.520-532, 2016 (SCI-Expanded, Scopus)
2016
2016108. Lack of Association between Pulse Steroid Therapy and Bone Mineral Density in Patients with Multiple Sclerosis
Karahan S. Z., BOZ C., Kilic S., Usta N. C., Ozmenoglu M., ALTUNAYOĞLU ÇAKMAK V., et al.
MULTIPLE SCLEROSIS INTERNATIONAL
, cilt.2016, 2016 (ESCI)
2016
2016109. Demiyelizan Hastalıklar ve Önlenebilir Acil Durumlar
ALTIPARMAK D., BOZ C.
türkiye klinikleri , 2016 (TRDizin)
2015
2015110. Defining reliable disability outcomes in multiple sclerosis
Kalincik T., CUTTER G., Spelman T., Jokubaitis V., HAVRDOVA E., HORAKOVA D., et al.
BRAIN
, cilt.138, 2015 (SCI-Expanded, Scopus)
2015
2015111. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort Demographic, Clinical, and Laboratory Features
Altintas A., KARABUDAK R., Balci B. P., TERZİ M., Soysal A., Saip S., et al.
NEUROLOGIST
, cilt.20, sa.4, ss.61-66, 2015 (SCI-Expanded, Scopus)
2015
2015112. Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry
Rojas J. I., Patrucco L., Trojano M., Lugaresi A., Izquierdo G., Butzkueven H., et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
, cilt.1, 2015 (Scopus)
2015
2015113. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis
Kalincik T., Jokubaitis V., IZQUIERDO G., DUQUETTE P., GIRARD M., Grammond P., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.21, sa.9, ss.1159-1171, 2015 (SCI-Expanded, Scopus)
2015
2015114. Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS
Ribbons K. A., McElduff P., BOZ C., Trojano M., Izquierdo G., Duquette P., et al.
PLOS ONE
, cilt.10, sa.6, 2015 (SCI-Expanded, Scopus)
2015
2015115. BREMSO: a simple score to predict early the natural course of multiple sclerosis
BERGAMASCHI R., MONTOMOLI C., MALLUCCI G., LUGARESI A., IZQUIERDO G., GRAND'MAISON F., et al.
EUROPEAN JOURNAL OF NEUROLOGY
, cilt.22, sa.6, ss.981-989, 2015 (SCI-Expanded, Scopus)
2015
2015116. Predictors of disability worsening in clinically isolated syndrome
Jokubaitis V. G., Spelman T., Kalincik T., Izquierdo G., Grand'Maison F., Duquette P., et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
, cilt.2, sa.5, ss.479-491, 2015 (SCI-Expanded, Scopus)
2015
2015117. Patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder: Turkish Multicenter Data
Altintas A., Karabudak R., Balci B. P., Terzi M., Soysal A., SAİP S., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.21, sa.6, ss.824-825, 2015 (SCI-Expanded, Scopus)
2015
2015118. Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., et al.
ANNALS OF NEUROLOGY
, cilt.77, sa.3, ss.425-435, 2015 (SCI-Expanded, Scopus)
2014
2014119. Seasonal Variation of Relapse Rate in Multiple Sclerosis is Latitude Dependent
Spelman T., Gray O., Trojano M., Petersen T., Izquierdo G., Lugaresi A., et al.
ANNALS OF NEUROLOGY
, cilt.76, sa.6, ss.880-890, 2014 (SCI-Expanded, Scopus)
2014
2014120. Risk of relapse phenotype recurrence in multiple sclerosis
KALINCIK T., BUZZARD K., Jokubaitis V., TROJANO M., DUQUETTE P., IZQUIERDO G., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.20, sa.11, ss.1511-1522, 2014 (SCI-Expanded, Scopus)
2014
2014121. Evaluation of Temperament and Character Features as Risk Factors for Depressive Symptoms in Patients with Restless Legs Syndrome
Cakmak V., GAZİOĞLU S., USTA N. C., Ozkorumak E., AYAR A., TOPBAŞ M., et al.
JOURNAL OF CLINICAL NEUROLOGY
, cilt.10, sa.4, ss.320-327, 2014 (SCI-Expanded, Scopus)
2014
2014122. Factors associated with early hospital arrival in acute ischemic stroke patients
KOKSAL E. K., GAZİOĞLU S., BOZ C., ÇAN G., ALİOĞLU Z.
NEUROLOGICAL SCIENCES
, cilt.35, sa.10, ss.1567-1572, 2014 (SCI-Expanded, Scopus)
2014
2014123. Predictors and dynamics of postpartum relapses in women with multiple sclerosis
HUGHES S. E., SPELMAN T., GRAY O. M., BOZ C., TROJANO M., LUGARESI A., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.20, sa.6, ss.739-746, 2014 (SCI-Expanded, Scopus)
2014
2014124. Personality Traits of Patients With Multiple Sclerosis and Their Relationship With Clinical Characteristics
GAZİOĞLU S., Cakmak V. A., Ozkorumak E., USTA N. C., Ates C., BOZ C.
JOURNAL OF NERVOUS AND MENTAL DISEASE
, cilt.202, sa.5, ss.408-411, 2014 (SCI-Expanded, SSCI, Scopus)
2014
2014125. Fingolimod after natalizumab and the risk of short-term relapse
Jokubaitis V. G., Li V., Kalincik T., Izquierdo G., Hodgkinson S., Alroughani R., et al.
NEUROLOGY
, cilt.82, sa.14, ss.1204-1211, 2014 (SCI-Expanded, Scopus)
2014
2014126. Anomalik İnnervasyonlar
GAZİOĞLU S., BOZ C.
ürkiye Klinikleri Nöroloji Özel Dergisi- Elektromiyografi (EMG) Özel Sayısı , sa.6, ss.24-30, 2014 (Hakemli Dergi)
2014
2014127. Anti John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey
MEFKURE E., AĞAN K., AK F., ANLAR Ö., BALCI F. B., BOZ C., et al.
Journal of experimental and clinical Medicine , cilt.31, ss.31-36, 2014 (Hakemli Dergi)
2013
2013128. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
Kalincik T., VIVEK V., Jokubaitis V., LECHNER-SCOTT J., TROJANO M., IZQUIERDO G., et al.
BRAIN
, cilt.136, ss.3609-3617, 2013 (SCI-Expanded, Scopus)
2013
2013129. Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study
Iuliano G., BOZ C., Cristiano E., Duquette P., Lugaresi A., Oreja-Guevara C., et al.
JOURNAL OF NEUROLOGY
, cilt.260, sa.5, ss.1258-1262, 2013 (SCI-Expanded, Scopus)
2013
2013130. Fluctuations of MS births and UV-light exposure
VERHEUL F., SMOLDERS J., TROJANO M., LEPORE V., ZWANIKKEN C., AMATO M. P., et al.
ACTA NEUROLOGICA SCANDINAVICA
, cilt.127, sa.5, ss.301-308, 2013 (SCI-Expanded, Scopus)
2013
2013131. Clinical Characteristics and Prognosis of Guillain Barre Syndrome
GAZİOĞLU S., TOMAK T., BOZ C.
JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH
, cilt.30, sa.1, ss.124-134, 2013 (SCI-Expanded, Scopus, TRDizin)
2013
2013132. Cerebral venous thrombosis after high dose steroid in multiple sclerosis: a case report
GAZİOĞLU S., SOLMAZ D., BOZ C.
HIPPOKRATIA
, cilt.17, sa.1, ss.88-90, 2013 (SCI-Expanded, Scopus)
2012
2012133. Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis
Trojano M., Lucchese G., Graziano G., Taylor B. V., Simpson S., Lepore V., et al.
PLOS ONE
, cilt.7, sa.10, 2012 (SCI-Expanded, Scopus)
2012
2012134. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study
ALTINTAŞ A. T., PETEK B., ISIK N., Terzi M., BOLUKBASI F., TAVSANLI M., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.18, sa.10, ss.1448-1453, 2012 (SCI-Expanded, Scopus)
2012
2012135. Ocular and cervical vestibular evoked myogenic potentials in multiple sclerosis patients
GAZİOĞLU S., BOZ C.
CLINICAL NEUROPHYSIOLOGY
, cilt.123, sa.9, ss.1872-1879, 2012 (SCI-Expanded, Scopus)
2012
2012136. Magnetic resonance imaging in bilateral brachial neuritis with pure sensory involvement
GAZİOĞLU S., BOZ C., SARI A.
NEUROLOGICAL SCIENCES
, cilt.33, sa.4, ss.927-930, 2012 (SCI-Expanded, Scopus)
2012
2012137. Increasing age at disability milestones among MS patients in the MSBase Registry
Kister I., CHAMOT E., CUTTER G., Bacon T. E., JOKUBAITIS V. G., HUGHES S. E., et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES
, cilt.318, ss.94-99, 2012 (SCI-Expanded, Scopus)
2012
2012138. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude
LECHNER-SCOTT J., SPENCER B., DE MALMANCHE T., Attia J., Fitzgerald M., TROJANO M., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.18, sa.7, ss.974-982, 2012 (SCI-Expanded, Scopus)
2012
2012139. Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome
MEYNIEL C., SPELMAN T., JOKUBAITIS V. G., TROJANO M., IZQUIERDO G., GRAND'MAISON F., et al.
PLOS ONE
, cilt.7, sa.6, 2012 (SCI-Expanded, Scopus)
2012
2012140. Cervical vestibular evoked myogenic potentials to air-conducted sound in early amyotrophic lateral sclerosis
KILIC S., GAZİOĞLU S., ZENGIN K. S., DUBUS H. U., BOZ C.
NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY
, cilt.42, sa.3, ss.119-123, 2012 (SCI-Expanded, Scopus)
2012
2012141. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry
Hughes S., Spelman T., Trojano M., Lugaresi A., Izquierdo G., Grand'Maison F., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
, cilt.83, sa.3, ss.305-310, 2012 (SCI-Expanded, Scopus)
2012
2012142. Basilar artery occlusion in migraine-like headache: a possible triggering effect of sumatriptan
GAZİOĞLU S., BOZ C., Ozmenoglu M.
NEUROLOGICAL SCIENCES
, cilt.33, sa.1, ss.125-128, 2012 (SCI-Expanded, Scopus)
2011
2011143. The effect of pregnancy on relapse rate and disability progression in MS: results from the MSBase Registry
Hughes S. E., Spelman T., Gray O. M., Boz C., Trojano M., Zwanikken C., et al.
MULTIPLE SCLEROSIS JOURNAL
, cilt.17, 2011 (SCI-Expanded, Scopus)
2011
2011144. Ultra-annual changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicentre study
Iuliano G., Boz C., Cristiano E., Duquette P., Lugaresi A., Van Pesch V.
MULTIPLE SCLEROSIS JOURNAL
, cilt.17, 2011 (SCI-Expanded, Scopus)
2011
2011145. Electrodiagnosis of carpal tunnel syndrome in patients with diabetic polyneuropathy
GAZİOĞLU S., BOZ C., CAKMAK V. A.
CLINICAL NEUROPHYSIOLOGY
, cilt.122, sa.7, ss.1463-1469, 2011 (SCI-Expanded, Scopus)
2008
2008146. VEMP responses are not affected in non-insulin-dependent diabetes mellitus patients with or without polyneuropathy
BEKTAS D., GAZİOĞLU S., ARSLAN S., COBANOGLU B., BOZ C., CAYLAN R.
ACTA OTO-LARYNGOLOGICA
, cilt.128, sa.7, ss.768-771, 2008 (SCI-Expanded, Scopus)
2007
2007147. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study
Boz C., OGER J., GIBBS E., GROSSBERG S. E.
MULTIPLE SCLEROSIS
, cilt.13, sa.9, ss.1127-1137, 2007 (SCI-Expanded, Scopus)
2007
2007148. Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tension-type headache
Boz C., Gazioglu S., ALTUNAYOGLU V., HOCAOGLU C.
PSYCHIATRY AND CLINICAL NEUROSCIENCES
, cilt.61, sa.5, ss.534-542, 2007 (SCI-Expanded, Scopus)
2006
2006149. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in multiple sclerosis
Boz C.
CLINICAL NEUROLOGY AND NEUROSURGERY
, cilt.108, sa.6, ss.618, 2006 (SCI-Expanded, Scopus)
2006
2006150. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy
Kister I., Gulati S., Boz C., Bergamaschi R., Piccolo G., Oger J., et al.
ARCHIVES OF NEUROLOGY
, cilt.63, sa.6, ss.851-856, 2006 (SCI-Expanded, Scopus)
2006
2006151. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta
Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., et al.
Clinical Neurology and Neurosurgery
, cilt.108, sa.2, ss.124-128, 2006 (SCI-Expanded, Scopus)
2005
2005152. The impact of migraine on epilepsy: a prospective prognosis study
Velioglu S., Boz C., Ozmenoglu M.
CEPHALALGIA
, cilt.25, sa.7, ss.528-535, 2005 (SCI-Expanded, Scopus)
2004
2004153. Temperament and character profiles of patients with tension-type headache and migraine
Boz C., Velioglu S., Ozmenoglu M., Sayar K., Alioglu Z., Yalman B., et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES
, cilt.58, sa.5, ss.536-543, 2004 (SCI-Expanded, Scopus)
2004
2004154. Individual risk factors for carpal tunnel syndrome: an evaluation of body mass index, wrist index and hand anthropometric measurements
Boz C., Ozmenoglu M., Altunayoglu V., Velioglu S., Alioglu Z.
CLINICAL NEUROLOGY AND NEUROSURGERY
, cilt.106, sa.4, ss.294-299, 2004 (SCI-Expanded, Scopus)
2004
2004155. The efficacy and safety of dipyrone (Novalgin®) tablets in the treatment of acute migraine attacks: A double-blind, cross-over, randomized, placebo-controlled, multi-center study
Tulunay F. C., ERGÜN H., Gülmez S. E., Özbenli T., Özmenoǧlu M., Boz C., et al.
Functional Neurology
, cilt.19, sa.3, ss.197-202, 2004 (SCI-Expanded, Scopus)
2004
2004156. The efficacy and safety of dipyrone (Novalgin (R)) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study
Tulunay F., Ergun H., Gulmez S., Ozbenli T., Ozmenoglu M., Boz C., et al.
FUNCTIONAL NEUROLOGY
, cilt.19, sa.3, ss.197-202, 2004 (SCI-Expanded, Scopus)
2004
2004157. Guillain-Barre syndrome during treatment with interferon alpha for hepatitis B
BOZ C., OZMENOGLU M., AKTOZ G., VELIOGLU S., Alioglu Z.
JOURNAL OF CLINICAL NEUROSCIENCE
, cilt.11, sa.5, ss.523-525, 2004 (SCI-Expanded, Scopus)
2004
2004158. Transient Tic disorder following carbon monoxide poisoning
Alioglu Z., BOZ C., SARI A., AYNACI M.
JOURNAL OF NEURORADIOLOGY
, cilt.31, sa.3, ss.231-233, 2004 (SCI-Expanded, Scopus)
2004
2004159. Ocular myasthenia gravis associated with X-linked recessive spinal and bulbar muscular atrophy
Boz C., Kalay E., Sahin N., VELİOĞLU S., Ozmenoglu M., Karagüzel A.
Journal of Clinical Neuromuscular Disease
, cilt.5, sa.3, ss.115-118, 2004 (Scopus)
2004
2004160. Kronik gerilim tipi baş ağrılı hastalarda mizaç ve karakter profili
BOZ C., Sayar K., VELIOGLU S., Hocaoğlu Ç., ALİOĞLU Z., YALMAN B., et al.
Türk Psikiyatri Derg. , cilt.15, sa.2, ss.105-111, 2004 (SCI-Expanded, TRDizin)
2004
2004161. Benign acute childhood myositis
SONMEZ F., CAKIR M., YAYLA S., Boz C.
MEDICAL PRINCIPLES AND PRACTICE
, cilt.13, sa.4, ss.227-229, 2004 (SCI-Expanded, Scopus)
2004
2004162. Local cold effect on the excitability recovery curve of the sympathetic skin response
BOZ C., ÖZMENOĞLU M., ALİOĞLU Z., VELİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S.
electromyography and clinical neurophysiology
, 2004 (Hakemli Dergi)
2004
2004163. Temperament and character profile of patients with chronic tension-type headache Kronik Gerilim Tipi Baş Agrili Hastalarda Mizaç ve Karakter Profili.
BOZ C., Sayar K., VELİOĞLU S., HOCAOĞLU Ç., ALİOĞLU Z., Yalman B., et al.
Türk psikiyatri dergisi = Turkish journal of psychiatry
, cilt.15, sa.2, ss.105-111, 2004 (SCI-Expanded, Scopus, TRDizin)
2004
2004164. Isolated hypoglossal nerve palsy in a child
AYNACI F., SEN Y., Boz C., ORHAN F.
TURKISH JOURNAL OF PEDIATRICS
, cilt.46, sa.1, ss.101-103, 2004 (SCI-Expanded, Scopus)
2003
2003165. Sertraline versus amitriptyline in the prophylactic therapy of non-depressed chronic tension-type headache patients
BOZ C., Altunayoglu V., VELİOĞLU S., Ozmenoglu M.
Journal of Headache and Pain
, cilt.4, sa.2, ss.72-78, 2003 (SCI-Expanded, Scopus)
2003
2003166. Tissue plasminogen activator mass concentration in ischemic acute stroke patients
BOZ C., AKBAS A., ALİOĞLU Z., OZMENOGLU M.
Turkish Journal of Medical Sciences , cilt.33, sa.3, ss.155-159, 2003 (Scopus, TRDizin)
2003
2003167. Gebelik ve loğusalıkta akut strok olayları
ALİOĞLU Z., ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZMENOĞLU M.
Türk Serebrovasküler Hastalıklar Dergisi , cilt.9, sa.2, ss.63-66, 2003 (TRDizin)
2003
2003168. Central nervous system involvement in autoimmune polyglandular syndrome
Boz C., Velioglu S., Altunayoglu V., Ozmenoglu M., Erem C.
CLINICAL NEUROLOGY AND NEUROSURGERY
, cilt.105, sa.2, ss.102-104, 2003 (SCI-Expanded, Scopus)
2003
2003169. Plasma homocysteine in acute and subacute phases after ischemic stroke İskemi̇k strok'ta akut ve subakut dönem homosi̇stei̇ n düzeyleri̇
VELİOĞLU S., BOZ C., Ari N., Uydu H. A., Özmenoǧlu M.
Turk Beyin Damar Hastaliklar Dergisi
, cilt.9, sa.1, ss.1-5, 2003 (Scopus, TRDizin)
2003
2003170. Acute disseminated encephalomyelitis after bee sting
Boz C., Velioglu S., Omenoglu M.
NEUROLOGICAL SCIENCES
, cilt.23, sa.6, ss.313-315, 2003 (SCI-Expanded, Scopus)
2003
2003171. Diyabetik Nöropati
GAZİOĞLU S., BOZ C.
Galenos Tıp Dergisi
, ss.24-35, 2003 (Hakemli Dergi)
2003
2003172. Epilepsili hastalarda kognitif fonksiyonların olaya ilişkin endojen potansiyellerle (P300) değerlendirilmesi
BOZ C., VELIOGLU S., ALİOĞLU Z., OZMENOGLU M.
TÜRK NÖROLOJİ DERGİSİ , cilt.1, ss.53-61, 2003 (ESCI, Scopus, TRDizin)
2002
2002173. X-linked spinal and bulbar muscular atrophy without proximal atrophy
Boz C., Sahin N., Kalay E., Velioglu S., Ozmenoglu M.
CLINICAL NEUROLOGY AND NEUROSURGERY
, cilt.105, sa.1, ss.14-17, 2002 (SCI-Expanded, Scopus)
2002
2002174. Relationship between major depression and heart rate variability. Clinical consequences and implications for antidepressive treatment
Agelink M., Boz C., Ullrich H., Andrich J.
PSYCHIATRY RESEARCH
, cilt.113, sa.1-2, ss.139-149, 2002 (SCI-Expanded, SSCI, Scopus)
2002
2002175. Treatment of intractable hiccups Dirençli hiçkiriklarda tedavi
BOZ C., VELİOĞLU S., Özmenoǧlu M.
SENDROM
, cilt.14, sa.12, ss.70-73, 2002 (Scopus)
2002
2002176. Fatal brainstem infarction after apheresis donation.
BOZ C., VELİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ALİOĞLU Z., ÖZMENOĞLU M.
JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH , cilt.19, sa.3, ss.1-9, 2002 (TRDizin)
2002
2002177. Fatal brainstem infarction after apheresis donation
BOZ C., VELIOGLU S., Altunayoğlu Çakmak V., ALİOĞLU Z., OZMENOGLU M.
e-Journal of Neurological Sciences - Turkish , cilt.19, sa.3, ss.35-50, 2002 (SCI-Expanded, Scopus, TRDizin)
2002
2002178. Non-ketojenik hiperglisemiye bağlı hemibalismus-hemikore ve kraniyal magnetik rezonans görüntüleme
ALİOĞLU Z., BOZ C., OZMENOGLU M.
Parkinson Hastalığı ve Hareket Bozuklukları Dergisi , cilt.5, sa.2, ss.62-66, 2002 (Hakemsiz Dergi)
2002
2002179. Evaluation of plasma endothelin-1 levels in patients with cerebral infarction
Alioglu Z., OREM A., BULBUL I., BOZ C., OZMENOGLU M., VANIZOR B.
ANGIOLOGY
, cilt.53, sa.1, ss.77-82, 2002 (SCI-Expanded, Scopus)
2002
2002180. Eklamptik ve preeklamptik olgularda elektroensefalografi ve kraniyal magnetik rezonans görüntüleme bulguları
ALİOĞLU Z., VELIOGLU S., Dinç G., BOZ C., DINC H., OZMENOGLU M.
EPILEPSY , cilt.1, ss.21-25, 2002 (Scopus)
2002
2002181. The Effects of Pentoxifylline in Experimental Nerve Injury
BAYKAL S., BOZ C., ÇAKIR E., BAYTAN Ş. H., KARAKUŞ M., KUZEYLİ K.
TURKISH JOURNAL OF MEDICAL SCIENCES , sa.32, ss.207-210, 2002 (Scopus, TRDizin)
2001
2001182. Baclofen is effective in intractable hiccups induced by brainstem lesions
Boz C., Velioglu S., Bulbul I., Ozmenoglu M.
NEUROLOGICAL SCIENCES
, cilt.22, sa.5, ss.409, 2001 (SCI-Expanded, Scopus)
2001
2001183. Status epilepticus after stroke
VELIOGLU S., OZMENOGLU M., BOZ C., Alioglu Z.
STROKE
, cilt.32, sa.5, ss.1169-1172, 2001 (SCI-Expanded, Scopus)
2001
2001184. Cerebral infarction following intravenous immunoglobulin therapy for Guillain-Barre syndrome
VELİOĞLU S., Özmenoǧlu M., BOZ C.
Journal of Stroke and Cerebrovascular Diseases
, cilt.10, sa.6, ss.290-292, 2001 (SCI-Expanded, Scopus)
2000
2000185. Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage
ALIOGLU Z., Bülbül İ., ÖREM A., OZMENOGLU M., KURAL B., BOZ C.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES , cilt.9, sa.4, ss.176-180, 2000 (Scopus)
2000
2000186. Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage
ALIOGLU Z., Bülbül İ., ÖREM A., OZMENOGLU M., KURAL B., BOZ C.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES , cilt.9, sa.4, ss.176-180, 2000 (Scopus)
2000
2000187. Serebrovasküler hastalık sonrası gelişen epilepsi nöbetleri.
VELİOĞLU S., BOZ C., ALİOĞLU Z., OZMENOGLU M., Yalman B.
TÜRK NÖROLOJİ DERGİSİ , cilt.6, sa.4, ss.39-45, 2000 (ESCI, Scopus, TRDizin)
2000
2000188. Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage
ALİOĞLU Z., BULBUL I., OREM A., OZMENOGLU M., VANIZOR B., BOZ C.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES , cilt.9, ss.176-180, 2000 (SCI-Expanded, Scopus)
2000
2000189. Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage
ALİOĞLU Z., Bülbül I., ÖREM A., Özmenoǧlu M., KURAL B., BOZ C.
Journal of Stroke and Cerebrovascular Diseases
, cilt.9, sa.4, ss.176-180, 2000 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2024
20241. Real-world experience with Cladribine (Mavenclad) in the MSBase registry
Butzkueven H., Spelman T., Van der Walt A., Hodgkinson S., Ozakbas S., Alroughani R., et al.
40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, ss.364-365, (Özet Bildiri)
2024
20242. Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years
Roberts J., Sharmin S., Horakova D., Havrdova E., Ozakbas S., Lugaresi A., et al.
40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, ss.357-360, (Özet Bildiri)
2023
20233. MULTİPL SKLEROZ TEDAVİSİNDE DİMETİL FUMARATIN İKİ YILLIK TÜRKİYE GERÇEK YAŞAM VERİSİ
TERZİ M., ŞEN S., BECKMANN Y., KARABUDAK R., HELVACI E. M., YETKİN M. F., et al.
59.Ulusal Nöroloji Kongresi, Antalya, Türkiye, 13 - 18 Aralık 2023, (Özet Bildiri)
2023
20234. The Effect of Pregnancy on Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Associated Disease Activity and Progression: A Multi-center Retrospective Study from Turkey
Uzunkopru C., Şen S., Altintas A., ÇAKAN ERCAN M., BÜNÜL S. D., Demir G. A., et al.
9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.664, (Özet Bildiri)
2022
20225. AN UNUSUAL REASON OF BACK PAIN AND WEAKNESS: SPINAL CORD INFARCTION
CANDAŞ K. B., KURŞUN S., GÜL K., YÜKSEL Z. Ö., İMAMOĞLU M., ÖZER V., et al.
17th WINFOCUS WORLD CONGRESS & 8th EURASIAN CONGRESS ON EMERGENCY MEDICINE, Türkiye, 1 - 04 Aralık 2022, (Özet Bildiri)
2022
20226. GEBELİĞİN NÖROMYELİTİS OPTİKA SPEKTRUM HASTALIĞI (NMOSD) VE MYELİN OLİGODENDROSİT GLİKOPROTEİN İLİŞKİLİ HASTALIK (MOGAD) PROGNOZU ÜZERİNE ETKİLER
UZUNKÖPRÜ C., GÜNDÜZ T., BOZ C., GÜLER S.
58. Ulusal Nöroloji Kongresi (Uluslararası Katılımlı), Antalya, Türkiye, 19 Kasım 2022, (Tam Metin Bildiri)
2022
20227. Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study
Butzkueven H., Spelman T., ÖZAKBAŞ S., Laureys G., Van Hijfte L., Alroughani R., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.384-386, (Özet Bildiri)
2022
20228. Emulating randomized clinical trials in relapsing-remitting multiple sclerosis with nonrandomized real-world evidence: an application using data from the MSBase registry
Ponzano M., ÖZAKBAŞ S., Horakova D., Havrdova E., Terzi M., Alroughani R., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.379-380, (Özet Bildiri)
2022
20229. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Sharmin S., Roos I., Simpson-Yap S., Malpas C., Sanchez M. M., ÖZAKBAŞ S., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.967-970, (Özet Bildiri)
2022
202210. Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS
Kalincik T., Sharman S., Roos I., Freedman M., Atkins H., Burman J., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.11-14, (Özet Bildiri)
2022
202211. A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis
Roos I., Hughes S., MacDonnell G., Boz C., Alroughani R., Ozakbas S., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.951-953, (Özet Bildiri)
2022
202212. Medulla oblongata volume measured from clinical routine T2-FLAIR scans is associated with disability progression in a multiple sclerosis real-world dataset
Bergsland N., Barnett M., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.289-290, (Özet Bildiri)
2022
202213. Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation
Zhu C., Kalincik T., Horakova D., Zhen Z., Buzzard K., Skibina O., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.645-647, (Özet Bildiri)
2022
202214. Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi-National Registry (P17-4.001)
Kalincik T. K., TERZİ M., TÜRKOĞLU R., BOZ C., ALTINTAŞ A., Malpas C. B. M., et al.
American Academy of Neurology, Seattle, Amerika Birleşik Devletleri, 20 Mayıs 2022, cilt.98, ss.17, (Tam Metin Bildiri)
2020
202015. Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis
Spelman T., Acosta C., Hyde R., Campbell N., Havrdova E., Horakova D., et al.
8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 - 13 Eylül 2020, cilt.26, ss.526-527, (Özet Bildiri)
0
016. Distal Tübüler Asidoz, Osteopetrozis ve Serebral Kalsifikasyonu Olan Bir Vaka,?
KAYNAR R. K., BOZ C., ULUSOY Ş., ÖZMENOĞLU M., Gül S.
4. Ulusal Hipertansiyon ve Böbrek Hastalıkları Kongresi,, Antalya, Türkiye, ss.56, (Tam Metin Bildiri)
0
017. Distal Tübüler Asidoz, Osteopetrozis ve Serebral Kalsifikasyonu Olan Bir Vaka,?
KAYNAR R. K., BOZ C., ULUSOY Ş., ÖZMENOĞLU M., Gül S.
4. Ulusal Hipertansiyon ve Böbrek Hastalıkları Kongresi,, Antalya, Türkiye, ss.56, (Tam Metin Bildiri)
2020
202018. Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis
Kalincik T., Ibrahima D., Malpas C., Horakova D., Havrdova E., Trojano M., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Kanada, 25 Nisan - 01 Mayıs 2020, (Özet Bildiri)
2020
202019. Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)
Sharmin S., Bovis F., Malpas C. B., Horakova D., Trojana M., BOZ C., et al.
American Academy of Neurology, Amerika Birleşik Devletleri, 14 - 26 Nisan 2020, cilt.94, ss.2002, (Tam Metin Bildiri)
2020
202020. Identification of Therapeutic Lag in Multiple Sclerosis (1787)
Roos I., Leray E., Frascoli F., Horakova D., Trojana M., ÖZAKBAŞ S., et al.
American Academy of Neurology, Amerika Birleşik Devletleri, 14 - 19 Nisan 2020, cilt.94, ss.1787, (Tam Metin Bildiri)
2020
202021. Identification of Therapeutic Lag in Multiple Sclerosis
ROOS I., Leray E., FRASCOLİ F., Casey R., Horakova D., Havrdova E., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Kanada, 25 Şubat - 01 Mart 2020, (Özet Bildiri)
2020
202022. Determinants of Therapeutic Lag in Multiple Sclerosis (2059)
Roos I., Leray E., Frascoli F., Horakova D., Trojano M., Patti F., et al.
American Academy of Neurology, Amerika Birleşik Devletleri, 14 - 27 Nisan 2020, cilt.94, ss.2059, (Tam Metin Bildiri)
2019
201923. of Therapeutic Lag in Relapsing Multiple Sclerosis
ROOS I., FRASCOLİ F., Horakova D., Havrdova E., Trojano M., Izquierdo G., et al.
Conference of MS-Research-Australia, 31 Ekim - 01 Kasım 2019, (Özet Bildiri)
2019
201924. Multipl Skleroz Hastalarında Fingolimod Tedavisinin Etkililiği : Türkiye Gerçek Yaşam Verileri
TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., EKMEKÇİ Ö., et al.
55. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 15 - 21 Kasım 2019, (Özet Bildiri)
2019
201925. SS-78 GEÇ VE ERKEN BAŞLANGIÇLI MULTİPLE SKLEROZHASTALARINDA, KLİNİK VE HASTALIK PROGRESYONUFARKLILIKLARI
ZENGIN KARAHAN S., bilgiç a. b., KARAMAN A. G., BOZ C., TERZİ M.
55. Ulusal Nöroloji Kongresi, Türkiye, 15 - 21 Kasım 2019, (Tam Metin Bildiri)
2018
201826. SS-46 OCRELİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİLERİ:3 MULTİPL SKLEROZ MERKEZİNİN TECRÜBELERİ
VURAL E., TERZİ M., Sunter G., AĞAN YILDIRIM K., BOZ C.
55. Ulusal Nöroloji Kongresi, Türkiye, 15 Kasım 2018 - 21 Kasım 2019, (Tam Metin Bildiri)
2019
201927. BİR ULUSAL ÇALIŞMANIN YÖNTEMİ (ENVIROPIMS): YENİ TANI ALMIŞ ERİŞKİN, ERGEN VE ÇOCUK MULTİPLE SKLEROZ(MS) OLGULARINDA OBEZİTE, SAĞLIKLI BESLENME VE FİZİKSEL AKTİVİTE DURUMUNUN ARAŞTIRILMASI
YÜCEYAR A. N., AKMAN DEMİR G., ALTUNRENDE B., BECKMANN Y., BOZ C., CANBAZ KABAY S., et al.
55. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 15 - 21 Kasım 2019, (Özet Bildiri)
2019
201928. TEP-147 MULTİPL SKLEROZ HASTALARINDA FİNGOLİMODTEDAVİSİNİN ETKİLİLİĞİ : TÜRKİYE GERÇEK YAŞAMVERİLERİ (REFINE)
TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., Ekmekci Ö., et al.
55. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 16 - 20 Kasım 2019, ss.276, (Özet Bildiri)
2019
201929. SS-77 BİR ULUSAL ÇALIŞMANIN YÖNTEMİ (ENVIROPIMS):YENİ TANI ALMIŞ ERİŞKİN, ERGEN VE ÇOCUK MULTİPLESKLEROZ(MS) OLGULARINDA OBEZİTE, SAĞLIKLIBESLENME VE FİZİKSEL AKTİVİTE DURUMUNUNARAŞTIRILMASI
YÜCEYAR A. N., AKMAN G., ALTUNRENDE B., BECKMANN Y., BOZ C., CANBAZ KABAY S., et al.
55. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 16 - 20 Kasım 2019, ss.45, (Tam Metin Bildiri)
2019
201930. Self-management and coping strategies in patients with multipl sclerosia multicenter -prospective study
BOZ C., ÜNAL A., AKÇALI A., ALTUNRENDE B.
ECTRIMS, 11 - 13 Eylül 2019, (Özet Bildiri)
2019
201931. Real-world experience with Ocrelizumab in the MSBase Registry
Butzkueven H., Spelman T., Patti F., Ozakbas S., Eichau S., Alroughani R., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.539-540, (Özet Bildiri)
2019
201932. Modifiers of the effectiveness of MS immunotherapies
Kalincik T., Malpas C., Sharmin S., Horakova D., Havrdova E. K., Trojano M., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.791-793, (Özet Bildiri)
2019
201933. Determinants of therapeutic lag in relapsing multiple sclerosis
Roos I., Frascoli F., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.559-561, (Özet Bildiri)
2019
201934. Real-life outcomes of Ocrelizumab treatment from 3 multiple sclerosis centers in Turkey
Vural E., Terzi M., Sunter G., Gunal D., Agan K., Boz C.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.751, (Özet Bildiri)
2019
201935. MS cohorts and treatment utilization in academic centres in the Middle East
Moradi N., Sharmin S., Malpas C., Ozakbas S., Shaygannejad V., Alroughani R., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.394, (Özet Bildiri)
2019
201936. Therapeutic lag in relapsing multiple sclerosis
Roos I., Frascoli F., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.564-565, (Özet Bildiri)
2019
201937. Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression
De Brouwer E., Peeters L., Becker T., Altintas A., Soysal A., Van Wijmeersch B., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.63-65, (Özet Bildiri)
2019
201938. Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up
Boz C., Terzi M., Ozakbas S., Yuceyar N., Efendi H., Balci B. P., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.870, (Özet Bildiri)
2019
201939. Aggressive form of multiple sclerosis can be predicted early after disease onset
Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.605-607, (Özet Bildiri)
2019
201940. Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data
Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.788-790, (Özet Bildiri)
2019
201941. Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
Sharmin S., Lefort M., Andersen J., Horakova D., Havrdova E. K., Alroughani R., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.786-788, (Özet Bildiri)
2019
201942. Multiple Sclerosis Severity Score (MSSS) helps predict relapses and recovery from disability in patients treated for multiple sclerosis in the MSBase model
Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., Havrdova E. K., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.186-188, (Özet Bildiri)
2019
201943. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS
Kalincik T., Malpas C. B., Sharmin S., Roos I., Patti F., Butzkueven H., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.912-914, (Özet Bildiri)
2019
201944. Predicting long-term sustained disability progression in multiple sclerosis
Sharmin S., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., Eichau S., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.119-121, (Özet Bildiri)
2019
201945. Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder
Kunchok A., Malpas C., Nytrova P., Havrdova E., Alroughani R., TERZİ M., et al.
71st Annual Meeting of the American-Academy-of-Neurology (AAN), Pennsylvania, Amerika Birleşik Devletleri, 4 - 10 Mayıs 2019, cilt.92, (Özet Bildiri)
2018
201846. MULTİPL SKLEROZDA FİNGOLİMOD TEDAVİSİ SONRASI GELİŞEN GEBELİĞİN HASTALIK SEYRİNE OLAN ETKİSİ
TERZİ M., EVİN Ö., BOZ C., ONAR M. K.
MS DAYS V, KYRENIA, 2 - 04 Kasım 2018, ss.15, (Tam Metin Bildiri)
2018
201847. Determinants of disability accumulation in secondary-progressive multiple sclerosis
Lizak N., Malpas C., Sharmin S., Havrdova E., Horakova D., Izquierdo G., et al.
34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.30, (Tam Metin Bildiri)
2018
201848. Familial multiple sclerosis: comparing demographic and clinical characteristics with sporadic form
Eichau S., Spelman T., Izquierdo G., Laffaldano P., OrejaGuevara C., Butzkueven H., et al.
34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.31, (Tam Metin Bildiri)
2018
201849. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry
Spelman T., Havrdova E., Horakova D., Izquierdo G., Kalincik T., Lugaresi A., et al.
34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.31, (Tam Metin Bildiri)
2018
201850. RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the ’xxRELOMS-T’xx
SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., et al.
34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.100, (Özet Bildiri)
2018
201851. RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the 'RELOMS-T'
Sevim S., Demirkiran M., Terzi M., Yuceyar A. N., Tasdelen B., Idiman E., et al.
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.174, (Özet Bildiri)
2018
201852. Variability in scoring the functional system scores of the expanded disability status scale at clinics from different countries
Hum S., Brown R., Lapierre Y., Fellows L., Mayo N., Havrdova E. K., et al.
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.155-156, (Özet Bildiri)
2018
201853. Methylprednisolone concentration in milk and serum during and shortly after IV pulse therapy in patients with MS
Boz C., Ozer B., Terzi M., Karahan S. Z., Sen S., Mavis M., et al.
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.978, (Özet Bildiri)
2018
201854. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.
Spelman T., Harvrdova E. K., Horakova D., Izquierdo G., Kalincik T., Lugaresi A., et al.
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.25-26, (Özet Bildiri)
2018
201855. Investigation of the Clinical and Morphometric Changes Before and After Acupuncture Treatment in Patients with Bell’s Paralysis
ERTEMOĞLU ÖKSÜZ C., KALAYCIOĞLU A., YILDIRIM A., UZUN Ö., KALKIŞIM Ş. N., BOZ C., et al.
1.Uluslararası Geleneksel ve Tamamlayıcı Tıp Kongresi, 19 - 22 Nisan 2018, (Tam Metin Bildiri)
2018
201856. Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry
Kister I., Bacon T., Shaygannejad V., Havrdova E., Alroughani R., TERZİ M., et al.
70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)
2018
201857. A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
Spelman T., Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., et al.
70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)
2018
201858. Let's raise the awareness of MS specialists concerning the frequency and impact of RLS in MS and consequently the life quality of patients with MS: Striking results of the 'RELOMS-T' Study
Sevim S., Demirkiran M., TERZİ M., Yuceyar N., Tasdelen B., İDİMAN E., et al.
70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)
2017
201759. Susac Syndrome: Clinical Features, Laboratory Testing and Treatment Responses of 3 Cases
Ozmenoglu M., Karahan S. Z., Usta N. C., BOZ C.
10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 Kasım 2017, cilt.24, ss.421, (Özet Bildiri)
2017
201760. De Novo Trigeminal Neuralgia Induced by Dalfampridine (4-aminopyridine):3 Cases
Ozmenoglu M., BOZ C., Seker D., Horozoglu H.
10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 Kasım 2017, cilt.24, ss.379, (Özet Bildiri)
2017
201761. Multipl Skleroz artık HBS sekonder nedenleri arasında yerini almalı: Bu alanda şimdiye kadar yapılmış en geniş çaplı çalışmanın (Multipl sklerozun huzursuz bacakları-Türkiye) (RELOMS-T)) çarpıcı sonuçları
SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., et al.
53. Ulusal Nöroloji Kongresi, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)
2017
201762. MULTİPL SKLEROZDA FAMPRİDİNE TEDAVİSİ SONRASI TRİGEMİNAL NEVRALJİ
TERZİ M., BOZ C., ŞENER M., BEKIR Ö., ŞEN S.
53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)
2017
201763. MULTIPL SKLEROZ’DA MORTALİTE
TERZİ M., BOZ C., KIZILATEŞ G., ŞEN S., BEKIR Ö.
53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)
2017
201764. Susac Syndrome: Clinical features, Laboratory Testing and Treatment Response of 3 cases
ÖZMENOĞLU M., ZENGİN KARAHAN S., CAN USTA N., BOZ C.
10th Congress of the Pan-Asian Committe for Treatment and Research in Multiple Sclerosis, 23 - 25 Kasım 2017, (Tam Metin Bildiri)
2017
201765. Ms Tedavisinde Kullanılan İlaçların Kesilme Oranları ve Nedenleri
Çağlar Okumuş A., BOZ C., TERZİ M., ÖZAKBAŞ S., Türkoğlu R., Soysal A., et al.
53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)
2017
201766. Orta ve Doğu Karadeniz Bölgesinde Pediyatrik ve Yetişkin Multipl Skleroz Hastalarının Demografik ve Klinik Özellikleri
Şipal C., Akçaoğlu Y., BOZ C., TERZİ M.
53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.87, (Özet Bildiri)
2017
201767. MULTIPL SKLERODA DİMETİL FUMARAT TEDAVİSİ GERÇEK YAŞAM VERİSİ
TERZİ M., BOZ C., ŞEN S., GÜLER S., ÇİLİNGİR V., ŞENER M.
53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.229, (Özet Bildiri)
2017
201768. MULTİPL SKLEROZ’DA NATALİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİSİ
TERZİ M., BOZ C., ÇİLİNGİR V., ŞEN S., ŞENER M., GÜLER S.
53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.229-230, (Özet Bildiri)
2017
201769. MULTİPL SKLEROZ HASTALARINDA GLATİRAMER ASETAT TEDAVİSİNİN GÜNLÜK VE HAFTADA 3 KULLANIMI İLAÇ MEMNUNİYETİ
TERZİ M., BOZ C., BİLGE N., ÇİLİNGİR V., BEKIR Ö., BIÇAKCI D., et al.
53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.230-231, (Özet Bildiri)
2017
201770. MS TEDAVİSİNDE KULLANILAN İLAÇLARIN KESİLME ORANLARI VE NEDENLERİ
ÇAĞLAR OKUMUŞ A., BOZ C., TERZİ M., ÖZAKBAŞ S., TÜRKOĞLU R., SOYSAL A., et al.
53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.293, (Özet Bildiri)
2017
201771. MS TEDAVİSİNDE TERİFLUNOMİDE VE FİNGOLUMOD’UN KARŞILAŞTIRMALI ETKİNLİK VERİLERİ
BOZ C., ÖZAKBAŞ S., TERZİ M., TÜRKOĞLU R., SOYSAL A., TUNCER M. A., et al.
53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.54-55, (Özet Bildiri)
2017
201772. MS Tedavisinde Teriflunomide ve Fingolimod’un Karşılaştırmalı Etkinlik Verileri
BOZ C., ÖZAKBAŞ S., TERZİ M., Türkoğlu R., Soysal A., TUNCER M. A., et al.
53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.54, (Özet Bildiri)
2017
201773. MULTİPL SKLEROZDA MORTALİTE
TERZİ M., BOZ C., KIZILATEŞ EVİN G., ŞEN S., BEKİR Ö.
53. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.53, (Özet Bildiri)
2017
201774. MULTİPL SKLEROZ ARTIK HBS SEKONDER NEDENLERİ ARASINDA YERİNİ ALMALI!: BU ALANDA ŞİMDİYE KADAR YAPILMIŞ EN GENİŞ ÇAPLI ÇALIŞMANIN [MULTİPL SKLEROZUN HUZURSUZ BACAKLARI-TÜRKİYE (RELOMS-T)] ÇARPICI SONUÇLARI
SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., et al.
53. ULUSAL NÖROLOJİ KONGRE, Türkiye, 24 Kasım 2017 - 30 Ocak 2018, ss.54, (Özet Bildiri)
2017
201775. Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis
Kister A., Spelman T., Patti A., duguette A., TROJANO M., Izquierdo G., et al.
MULTIPLE SCLEROSIS JOURNAL, Paris, Fransa, 25 - 28 Ekim 2017, (Özet Bildiri)
2017
201776. METHYLPREDNİSOLONE CONCENTRATİONS İN BREAST MİLK AND SERUM İN PATİENT WİTH MULTİPLE SCLEROSİS TREATED IV PULSE METHYLPREDNİSOLONE
BOZ C., TERZİ M., KARAHAN S., ŞEN S., SARAÇ Y., MAVİŞ E.
ECTRIMS 2017, 25 - 28 Ekim 2017, (Özet Bildiri)
2017
201777. Prognostic value of MRI activity in treatment failure
Kunchok A. C., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.988-990, (Özet Bildiri)
2017
201778. Methylprednisolone concentrations in breast milk and serum in patients with multiple sclerosis treated with IV pulse methylprednisolone
Boz C., Terzi M., Karahan S. Z., Ozbudun B., Sen S., Sarac Y., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.462, (Özet Bildiri)
2017
201779. Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis
Jokubaitis V. G., Havrdova E., Horakova D., Izquierdo G., Kalincik T., van der Walt A., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.130-132, (Özet Bildiri)
2017
201780. Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years
Kalincik T., Spelman T., Jokubaitis V., Horakova D., Havrdova E., Trojano M., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.361-363, (Özet Bildiri)
2017
201781. Silent lesions on MRI - shifting goal post for treatment decisions in MS
Min M., Lechner-Scott J., Spelman T., Sola P., Granella F., Butzkueven H., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.393-394, (Özet Bildiri)
2017
201782. Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis
Boz C., Ozakbas S., Terzi M., Turkoglu R., Akman G., Efendi H., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.327-328, (Özet Bildiri)
2017
201783. The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis
Brown J. W. L., Lugaresi A., Horakova D., Havrdova E., Jokubaitis V., Lechner-Scott J., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.992-994, (Özet Bildiri)
2017
201784. Contribution of inflammation to disability accrual in primary progressive multiple sclerosis
Hughes J., Jokubaitis V., Spelman T., Lugaresi A., Hupperts R., Izquierdo G., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.399-401, (Özet Bildiri)
2017
201785. Susac syndrome: clinical features, laboratory testing and treatment responses of 20 cases
Karahan S. Z., Boz C., Usta N. C., Saip S., Kale N., Demirkaya S., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.90-91, (Özet Bildiri)
2017
201786. Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis
Merkel B., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.71-73, (Özet Bildiri)
2017
201787. Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study
Kalincik T., Spelman T., Jokubaitis V., Horakova D., Havrdova E., Izquierdo G., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.325-327, (Özet Bildiri)
2017
201788. Risk of secondary progressive multiple sclerosis: a longitudinal study
Fambiatos A., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.109-112, (Özet Bildiri)
2017
201789. A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS
Spelman T., Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.395-397, (Özet Bildiri)
2017
201790. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis
Boz C., Terzi M., Karahan S. Z., Sen S., Sarac Y., Mavis M.
3rd Congress of the European-Academy-of-Neurology, Amsterdam, Hollanda, 01 Haziran 2017, cilt.24, ss.490, (Özet Bildiri)
2017
201791. Pediatrik başlangıçlı multiple skleroz ile erişkin başlangıçlı multiple sklerozun klinik özelliklerinin karşılaştırılması
KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DURGUT B. D., DİLBER B., et al.
19. Ulusal Çocuk Nörolojisi Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)
2017
201792. Pediatrik başlangıçlı multipl skleroz ile erişkin başlangıçlı multipl sklerozun klinik özelliklerinin karşılaştırılması.
KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., et al.
19. Ulusal Çocuk Nörolojisi Kongresi, Kıbrıs (Kktc), 19 - 23 Nisan 2017, (Özet Bildiri)
2016
201693. Spinal anestezi sonrası gelişen unilateral abducens sınır paralizisi
KARAMAN A., GAZİOĞLU S., GÜRSOY M., ALTUNAYOĞLU ÇAKMAK V., BOZ C.
52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016, (Özet Bildiri)
2016
201694. TEP 147 MS Tedavisinde Teriflunomide in Etkinlik ve Tolerabite Gerçek Yaşam Verileri
BOZ C., TERZİ M., TÜRKOĞLU R., AKMAN G., EFENDİ H., AKÇALI A., et al.
52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016
2016
201695. Wernicke ensefalopatisi: olgu sunumu
GÜRSOY M., AKPINAR R., ALTUNAYOĞLU ÇAKMAK V., BOZ C., GAZİOĞLU S.
52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016, (Özet Bildiri)
2016
201696. T1-T2 radikülopatiye bağlı horner sendromu olgusu
ŞENER S., ÖZTÜRK S., GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., BOZ C.
52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016, (Özet Bildiri)
2016
201697. Anti inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosisAuthor s J Lorscheider V Jokubaitis T Spelman G Izquierdo A Lugaresi E Havrdova D Horakova M Trojano P Duquette M Girard A Prat F Grand Maison R Hupperts P Grammond E Pucci C Boz P Sola D Spitaleri J Lechner Scott M Terzi V Van Pesch G Iuliano R Bergamaschi R Fernández Bolaños C Ramo Tello F Granella M E Rio C Oreja Guevara H Butzkueven T Kalincik MSBase Study Group
Lorscheider l., jocubatis v., spelman t., Izquierdo g., lugaresi a., hardova e., et al.
ECTRIMS 2016, 14 - 16 Eylül 2016, (Özet Bildiri)
2016
201698. Individual response to disease modifying therapies a global observational cohort studyAuthor s T Kalincik L Sobisek V Jokubaitis T Spelman D Horakova E Havrdova M Trojano G Izquierdo A Lugaresi M Girard A Prat P Duquette P Grammond P Sola R Hupperts F Grand Maison E Pucci C Boz R Alroughani V Van Pesch J Lechner Scott M Terzi R Bergamaschi G Iuliano F Granella D Spitaleri V Shaygannejad C Oreja Guevara M Slee R Ampapa F Verheul P McCombe J Olascoaga M P Amato S Vucic S Hodgkinson C Ramo S Flechter E Cristiano C Rozsa F Moore J L Sanchez Menoyo M L Saladino M Barnett H Butzkueven MSBase Study Group
Kalincik t., Sobisek l., jocubatis v., spelman t., Dana H., Eva H., et al.
ECTRIMS 2016, 13 - 16 Eylül 2016, (Özet Bildiri)
2016
201699. Comparison of 5 year treatment outcomes between alemtuzumab versus natalizumab fingolimod and interferon 1a
Kalincik T., Brown j., Robertson R., Willis m., Scolding N., Pearson O., et al.
ECTRIMS 2016, 13 - 16 Eylül 2016, (Özet Bildiri)
2016
2016100. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod
Fragoso Y. D., Alroughani R., Barnett M., Brooks J. B., Butzkueven H., Boz C., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.337-338, (Özet Bildiri)
2016
2016101. Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis
Lorscheider J., Jokubaitis V., Spelman T., Izquierdo G., Lugaresi A., Havrdova E., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.367-369, (Özet Bildiri)
2016
2016102. Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a
Kalincik T., Brown J. W., Robertson N., Willis M., Scolding N., Pearson O., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.829-832, (Özet Bildiri)
2016
2016103. Early disease modifying treatment delays disability accumulation in patients with pediatric onset clinically isolated syndrome suggestive of multiple sclerosis.
Iaffaldano P., Simone M., Lucisano G., Ghezzi A., Coniglio G., Morra V. B., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.62-63, (Özet Bildiri)
2016
2016104. Real-life data from efficacy of fingolimod treatment in multiple sclerosis patients in Turkey
Terzi M., Kurtuncu M., Eraksoy M., Karabudak R., Tuncer A., Altunrende B., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.310, (Özet Bildiri)
2016
2016105. Long-term disability trajectories in primary progressivs MS patients - a latent class growth analysis.
Signori A., Izquierdo G., Lugaresi A., Hupperts R., Grand'Maison F., Sola P., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.44-46, (Özet Bildiri)
2016
2016106. Outcomes of pregnancy in neuromyelitis optica patients: turkish multicenter study data
Altintas A., Uygunoglu U., Terzi M., Boz C., Saip S., Koseoglu M., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.405-406, (Özet Bildiri)
2016
2016107. Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide
Spelman T., Kalincik T., Trojano M., Grand'Maison F., Izquierdo G., Havrdova E., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.602-603, (Özet Bildiri)
2016
2016108. Individual response to disease modifying therapies: a global observational cohort study
Kalincik T., Sobisek L., Jokubaitis V., Spelman T., Horakova D., Havrdova E., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.358-360, (Özet Bildiri)
2016
2016109. Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer
Spelman T., Izquierdo G., Lugaresi A., Alroughani R., Duquette P., Boz C., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.600-602, (Özet Bildiri)
2016
2016110. Prospectively Tracking DiseaseCourse and Treatment Changes in Neuromyelitis Optica Using NMOBase a Global Online Registry Ilya Kister Tamar Bacon Vahid Shaygannejad JyhYung Hor Raed Alroughani Shannon Haas Murat Terzi Cavit Boz Javier Olascoaga Pamela McCombe Yara Fragoso AlessandraLugaresi Patrizia Sola Steve Vucic EugenioPucci Talal Al Harbi Seyed Aidin Sajedi Juan Ignacio Rojas Liliana Patrucco EdgardoCristiano Jose Alberto Suarez MagdaliniTsolaki Bruce Taylor Gerardo Iuliano Paschalis Devranis Mark Marriott HelmutButzkueven
Kister I., bocan t., Shaygannejad v., Yung Hor j., Alroughani r., Shannon h., et al.
aan2016, 12 - 18 Nisan 2016, (Özet Bildiri)
2016
2016111. Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry.
Kister I., Bacon T., Shaygannejad V., Hor J. Y., Alroughani R., Haas S., et al.
68th Annual Meeting of the American-Academy-of-Neurology (AAN), Vancouver, Kanada, 15 - 21 Nisan 2016, cilt.86, (Özet Bildiri)
2015
2015112. Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.
Butzkueven H., Spelman T., Kalincik T., Jokubaitis V., Zhang A., Pellegrini F., et al.
8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul, Güney Kore, 19 - 21 Kasım 2015, cilt.22, ss.418-419, (Özet Bildiri)
2015
2015113. MS te yeni fenotipik patolojik ve klinik sınıflama
BOZ C.
Ulusal Nöroloji kongresi, Türkiye, 29 Kasım - 01 Aralık 2015
2015
2015114. RRMS HASTALARINDA 12 AYLIK FİNGOLİMOD TEDAVİSİ SONUÇLARI: FİNE ÇALIŞMASI
AKMAN DEMİR G., Türkoğlu R., SAİP S., YÜCEYAR A. N., EFENDİ H., TURAN Ö. F., et al.
51. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 27 Kasım - 03 Aralık 2015, (Özet Bildiri)
2015
2015115. Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity
Spelman T., Izquierdo G., Alroughani R., Fernandez Bolaos R., Havrdova E., Horaova D., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.237-238, (Özet Bildiri)
2015
2015116. Defining secondary progressive multiple sclerosis
Lorscheider J., Buzzard K., Jokubaitis V., Spelman T., Havrdova E., Horakova D., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.798-800, (Özet Bildiri)
2015
2015117. 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort
Jokubaitis V. G., Spelman T., Kalincik T., Travaglini D., Paolicelli D., Duquette P., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.100-102, (Özet Bildiri)
2015
2015118. Lack of association between pulse steroid therapy and bone mineral density in patients with multiple sclerosis
KARAHAN S. C., BOZ C., USTA N. C., KILIC S., Ozmenoglu M., Altunayoglu V., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.773, (Özet Bildiri)
2015
2015119. Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis
Stewart T., Jokubaitis V., Spelman T., Havrdova E., Horakova D., Trojano M., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.726-728, (Özet Bildiri)
2015
2015120. Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS
Spelman T., Kalincik T., Jokubaitis V., Zhang A., Pellegrini F., Wiendl H., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.258-259, (Özet Bildiri)
2015
2015121. Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis
Lizak N., Lugaresi A., Alroughani R., Lechner-Scott J., Slee M., Havrdova E., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.308-310, (Özet Bildiri)
2014
2014122. Neuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort: demographic, clinical, laboratory and radiological features
Altintas A., Karabudak R., Balci B. P., Terzi M., Soysal A., Saip S., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.348-349, (Özet Bildiri)
2014
2014123. Comparison of fingolimod versus interferon beta/glatiramer acetate as second-line therapy in active multiple sclerosis
He A., Spelman T., Jokubaitis V., Lugaresi A., Izquierdo G., Trojano M., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.193, (Özet Bildiri)
2014
2014124. Evaluation of common criteria of progression of disability in a large observational cohort
Kalincik T., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.62-63, (Özet Bildiri)
2014
2014125. Independent predictors of time to relapse after CIS in high-risk patients
Spelman T., Meyniel C., Trojano M., Lugaresi A., Izquierdo G., Grand'Maison F., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.54, (Özet Bildiri)
2014
2014126. NMOBase is a Web-based, global observational registry for an 'orphan' disorder: neuromyelitis optica
Kister I., Bacon T., Alroughani R., Boz C., Cristiano E., Iuliano G., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.165, (Özet Bildiri)
2014
2014127. Predictors of disability accrual in multiple sclerosis patients on first-line therapy
Spelman T., Jokubaitis V., Izquierdo G., Duquette P., Grand'Maison F., Grammond P., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.405, (Özet Bildiri)
2014
2014128. Seasonal variation of relapse rate in MS is latitude-dependent
Spelman T., Gray O., Trojano M., Petersen T., Izquierdo G., Lugaresi A., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.218-219, (Özet Bildiri)
2014
2014129. Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.195-196, (Özet Bildiri)
2014
2014130. Rekürrenslerle giden ADEM Guillain Barre Sendromu birlikteliği: Olgu Sunumu
ŞAHİN S., KAMAŞAK T., Baba Ö., CANSU A., BOZ C.
16. Ulusal Çocuk Nöroloji Kongresi, Türkiye, 22 - 27 Haziran 2014, (Özet Bildiri)
2013
2013131. Head-to-head Comparisons of Interferon Beta and Glatiramer Acetate in Clinical Practice
Butzkueven H., Kalincik T., Jokubaitis V., Izguierdo G., Duquette P., Girard M., et al.
6th Congress of the Pan-Asian-Committee-on-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Kyoto, Japonya, 6 - 08 Kasım 2013, cilt.20, ss.927, (Özet Bildiri)
2014
2014132. Factors associated with early hospital arrival in acute ischemic stroke patients
Koksal E. K., Gazioglu S., Boz C., Can G., Alioglu Z.
Joint Congress of European Neurology, İstanbul, Türkiye, 31 Mayıs - 03 Haziran 2014, cilt.21, ss.353, (Özet Bildiri)
2014
2014133. Factors associated with early hospital arrival in acute ischemic stroke patients
Koksal E. K., Gazioglu S., Boz C., Can G., Alioglu Z.
Joint Congress of European Neurology, İstanbul, Türkiye, 31 Mayıs - 03 Haziran 2014, cilt.261, (Özet Bildiri)
2013
2013134. Multipl Skleroz hastalarında kişilik özellikleri ve klinik özelliklerle ilişkisi
GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ÖZKORUMAK KARAGÜZEL E., CAN USTA N., BOZ C.
49. Ulusal Nöroloji Kongresi, Trabzon, Türkiye, 15 - 21 Kasım 2013
2013
2013135. Multipl Skleroz hastalarında kisilik özellikleri ve klinik özelliklerle iliskisi
GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ÖZKORUMAK KARAGÜZEL E., USTA N. C., BOZ C.
49. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 15 - 21 Kasım 2013, ss.108, (Tam Metin Bildiri)
2013
2013136. Huzursuz bacaklar sendromlu hastaların mizaç ve karakter özellikleri
ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S., ÖZKORUMAK KARAGÜZEL E., USTA N. C., TOPBAŞ M., BOZ C.
14. Ulusal Uyku Tıbbı Kongresi, Muğla, Türkiye, 6 - 10 Ekim 2013, ss.9, (Tam Metin Bildiri)
2013
2013137. Relapse incidence in women and men throughout the course of multiple sclerosis: an MSBase cohort study
Kalincik T., Vivek V., Jokubaitis V., Lechner-Scott J., Trojano M., Izquierdo G., et al.
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Danimarka, 2 - 05 Ekim 2013, cilt.19, ss.28-30, (Özet Bildiri)
2013
2013138. Predictors of 12-month confirmed disability progression after onset of clinically isolated syndrome (CIS) suggestive of multiple sclerosis
Jokubaitis V. G., Spelman T., Trojano M., Izquierdo G., Grand'Maison F., Duquette P., et al.
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Danimarka, 2 - 05 Ekim 2013, cilt.19, ss.13-15, (Özet Bildiri)
2013
2013139. Symptomatology of multiple sclerosis relapses varies in relation to demographic and clinical factors
Kalincik T., Buzzard K., Trojano M., Duquette P., Girard M., Izquierdo G., et al.
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Danimarka, 2 - 05 Ekim 2013, cilt.19, ss.112-114, (Özet Bildiri)
2013
2013140. Head-to-head comparisons of preparations of interferon beta and glatiramer acetate: a series of quasi-randomised MSBase trials
Kalincik T., Trojano M., Izquierdo G., Duquette P., Girard M., Grammond P., et al.
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Danimarka, 2 - 05 Ekim 2013, cilt.19, ss.569-571, (Özet Bildiri)
2013
2013141. Defining secondary progressive multiple sclerosis: is it possible to diagnose early?
Spelman T., Trojano M., Duquette P., Izquierdo G., Lugaresi A., Grammond P., et al.
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Danimarka, 2 - 05 Ekim 2013, cilt.19, ss.38, (Özet Bildiri)
2013
2013142. Does switching to fingolimod from natalizumab result in short-term relapse exacerbation?
Jokubaitis V. G., Li V., Kalincik T., Izquierdo G., Hodgkinson S., Alroughani R., et al.
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Danimarka, 2 - 05 Ekim 2013, cilt.19, ss.55-56, (Özet Bildiri)
2012
2012143. Clinical And Radiological Characteristics Of Tumefactive Demyelinating Lesions: Follow-up Study
Altintas A., Petek B., Isik N., Terzi M., Bolukbasi F., Tavsanli M., et al.
5th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Beijing, Çin, 13 - 15 Eylül 2012, cilt.19, ss.656, (Özet Bildiri)
2012
2012144. PREDICTORS OF POSTPARTUM RELAPSES IN WOMEN WITH MULTIPLE SCLEROSIS: RESULTS FROM THE MSBASE REGISTRY
Hughes S. E., Spelman T., Gray O. M., Boz C., Trojano M., McDonnell G. V., et al.
Annual Meeting of the Association-of-British-Neurologists, Brighton, İngiltere, 28 - 31 Mayıs 2012, cilt.83, (Özet Bildiri)
2012
2012145. EXPOSURE TO INTERFERON-beta THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS
Hughes S., Spelman T., Gray O., Boz C., Trojano M., Zwanikken C., et al.
Annual Meeting of the Association-of-British-Neurologists, Brighton, İngiltere, 28 - 31 Mayıs 2012, cilt.83, (Özet Bildiri)
2012
2012146. Risk factors of reduced bone mass in patients with multiple sclerosis
Boz C., Karahan S. Z.
28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, Fransa, 10 - 13 Ekim 2012, cilt.18, ss.249, (Özet Bildiri)
2012
2012147. Male MS patients fare worse!
Ribbons K. A., McElduff P., Vetere S., Boz C., Trojano M., Zwanikken C., et al.
28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, Fransa, 10 - 13 Ekim 2012, cilt.18, ss.79-80, (Özet Bildiri)
2012
2012148. Seasonal variation of relapse rate and ultraviolet radiation levels are sinusoidal and their phase-shifted relationship is latitude-dependent
Spelman T., Gray O., Trojano M., Lugaresi A., Izquierdo G., Zwanikken C., et al.
28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, Fransa, 10 - 13 Ekim 2012, cilt.18, ss.83-84, (Özet Bildiri)
2011
2011149. Multiple sklerozda huzursuz bacaklar sendromu
ALTUNAYOĞLU ÇAKMAK V., CANATAN S., GAZİOĞLU S., BOZ C.
47. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 25 Kasım - 01 Aralık 2011, ss.68, (Tam Metin Bildiri)
2011
2011150. Multiple skleroz hastalarında uykusuzluk ve özellikleri
ALTUNAYOĞLU ÇAKMAK V., CANATAN S., GAZİOĞLU S., BOZ C.
47. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 25 Kasım - 01 Aralık 2011, ss.67, (Tam Metin Bildiri)
2011
2011151. Predictors of Confirmed Disability Progression after a First Demyelinating Event
Butzkueven H., Spelman T., Izquierdo G., Grand-Maison F., Trojano M., Zwanikken C., et al.
63rd AAN Annual Meeting, Hawaii, Amerika Birleşik Devletleri, 9 - 16 Nisan 2011, cilt.76, (Özet Bildiri)
2009
2009152. Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study
Eraksoy M., Akman-Demir G., Agan K., Gunal D., Us O., Saip S., et al.
19th World Congress of Neurology, Bangkok, Tayland, 24 - 30 Ekim 2009, cilt.285, (Özet Bildiri)
2009
2009153. Onset of relapses in multiple sclerosis: the effect of seasonal change in both the northern and southern hemisphere
Gray O., Jolley D., Gibson K., Trojano M., Zwanikken C., Grand'Maison F., et al.
25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Düsseldorf, Almanya, 9 - 12 Eylül 2009, cilt.15, (Özet Bildiri)
2009
2009154. Temporal Variation of Onset of Relapses in Multiple Sclerosis: Results from the Northern and Southern Hemispheres in the MSBase Registry
Gray O. M., Jolley D., Zwanikken C., Trojano M., Grand-Maison F., Duquette P., et al.
61st Annual Meeting of American-Academy-of-Neurology, Washington, Amerika Birleşik Devletleri, 28 - 29 Nisan 2009, cilt.72, (Özet Bildiri)
2008
2008155. Temporal variation of onset of relapses in multiple sclerosis is not seasonal: results from the MSBase registry
Gray O. M., Jolley D., Zwanikken C., Trojano M., Grand'Maison F., Duquette P., et al.
1st Congress of Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Kuala-Lumpur, Malezya, 21 - 22 Kasım 2008, cilt.15, ss.137-138, (Özet Bildiri)
2008
2008156. The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis
Gray O. M., Zwanikken C., Trojano M., Grand'Maison F., Duquette P., Grammond P., et al.
1st Congress of Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Kuala-Lumpur, Malezya, 21 - 22 Kasım 2008, cilt.15, ss.140, (Özet Bildiri)
2008
2008157. The Multiple Sclerosis Severity Score re-examined: Expanded Disability Status Scale rank stability in the MSBase dataset increases five years after onset of multiple sclerosis
Butzkueven H., Jolley D., Trojano M., Zwanikken C., Maison F. G., Duquette P., et al.
13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Kanada, 17 - 20 Eylül 2008, cilt.14, (Özet Bildiri)
2007
2007158. Reduced effectiveness of long-term interferon beta treatment on relapses in neutralising antibody-positive multiple sclerosis patients: a Canadian MS clinic-based study
Oger J., Boz C., Devonshire V., Hashimoto S., Hooge J., Kastrukoff L., et al.
23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS, Prague, Çek Cumhuriyeti, 11 - 14 Ekim 2007, cilt.13, (Özet Bildiri)
2007
2007159. Tumefactive demyelinating disease is immunologically different from multiple sclerosis
Boz C., Gazioglu S., Terzi M.
23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS, Prague, Çek Cumhuriyeti, 11 - 14 Ekim 2007, cilt.13, (Özet Bildiri)
2007
2007160. Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression.
Butzkueven H., Mechati S., Hoffmann M. W., Arruda W., Boz C., Bacile E., et al.
59th Annual Meeting of the American-Academy-of-Neurology, Massachusetts, Amerika Birleşik Devletleri, 28 Nisan - 05 Mayıs 2007, cilt.68, (Özet Bildiri)
2006
2006161. Bilateral talamik infaktlarda klinik ve radyolojik bulgular
GAZİOĞLU S., BOZ C., ALTUNAYOĞLU ÇAKMAK V.
42. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 12 - 17 Kasım 2006, ss.169, (Tam Metin Bildiri)
2006
2006162. Is the current trial definition of confirmed disability progression in multiple sclerosis an accurate measure of permanent disease progression?
Butzkueven H., Mechati S., Hoffmann M., Arruda W. O., Bacile E., Boz C., et al.
22nd Congress of the European-Committee-for-the-Treatment-and-Resarch-in-Multiple-Sclerosis, Madrid, İspanya, 27 - 30 Eylül 2006, cilt.12, (Özet Bildiri)
2005
2005163. The MSBase Global Web Registry: joining independent local patient databases for multi-centre research
Butzkueven H., Arruda W., Boz C., Chapman J., Cristiano E., Fiol M., et al.
18th World Congress of Neurology, Sydney, Avustralya, 5 - 11 Kasım 2005, cilt.238, (Özet Bildiri)
2005
2005164. Economic impact of primary headaches in Turkey: a university hospital-based study, part II
Karly N., Zarifoglu M., Ertas M., Saip S., Ozturk V., Bycakcy P., et al.
22nd Congress of the International-Headache-Society, Kyoto, Japonya, 9 - 12 Ekim 2005, cilt.25, ss.951, (Özet Bildiri)
2005
2005165. The MSBase Global Registry: a web platform for collaborative multiple sclerosis outcomes research
Butzkueven H., Arruda W., Boz C., Chapman J., Cristiano E., Deri N., et al.
21st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/10th Annual Meeting of Rehabilitation in MS, Thessaloniki, Yunanistan, 28 Eylül - 01 Ekim 2005, cilt.11, (Özet Bildiri)
2005
2005166. Human herpesvirus 6-7-8 and Chlamydia pneumoniae infection in multiple sclerosis
Boz C., Altunayoglu V., Acar O., Gazioglu S., Ozmenoglu M.
21st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/10th Annual Meeting of Rehabilitation in MS, Thessaloniki, Yunanistan, 28 Eylül - 01 Ekim 2005, cilt.11, (Özet Bildiri)
2005
2005167. Neutralising antibodies reduce the effect of interferon on relapse rate: the British Columbia experience, Canada
Boz C., Gibbs E., Grossberg S., Oger J.
21st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/10th Annual Meeting of Rehabilitation in MS, Thessaloniki, Yunanistan, 28 Eylül - 01 Ekim 2005, cilt.11, (Özet Bildiri)
2004
2004168. Multipl skleroz hastalarında serum ve BOS matriks metalloproteinaz 9 ve matriks metalloproteinaz doku inhibitörler 1 seviyelerinin interferon beta 1 tedavisi öncesi ve sonrası değerlendirilmesi
BOZ C., ÖZMENOĞLU M., KILINÇ K., ÖREM A., VELİOĞLU S., ALİOĞLU Z., et al.
40. Ulusal Nöroloji Kongresi, Trabzon, Türkiye, 29 Eylül - 03 Ekim 2004
2004
2004169. Multipl skleroz hastalarında serum ve BOS matriks metalloproteinaz- 9 ve matriks metalloproteinaz doku inhibitörler-1 seviyelerinin interferon beta-1 tedavisi öncesi ve sonrası degerlendirilmesi
BOZ C., ÖZMENOĞLU M., KILINC K., ÖREM A., VELİOĞLU S., ALİOĞLU Z., et al.
40. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 29 Eylül - 03 Ekim 2004, ss.317, (Tam Metin Bildiri)
2004
2004170. Multipl sklerozlu hastada viral enfeksiyonların kanıtları
ACAR Ö., ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZMENOĞLU M., ALİOĞLU Z., VELİOĞLU S.
40. Ulusal Nöroloji Kongresi,, Antalya, Türkiye, 29 Eylül - 03 Ekim 2004, ss.203, (Tam Metin Bildiri)
2004
2004171. NORMAL POPÜLASYONDA İNSAN HERPES VİRUS 6 VE 7 DNA SIKLIĞI
SANCAKTAR M., BOZ C., KAKLIKKAYA N., TOSUN İ., BURUK C. K., YAZICI Y., et al.
3.ULUSAL MOLEKÜLER VE TANISAL MİKROBİYOLOJİ KONGRESİ, Ankara, Türkiye, 28 Haziran 2004, (Özet Bildiri)
2003
2003172. Ağırlık kaldırma egsersizi sonrası gelişen spinal aksesöri sinir hasarı
ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZMENOĞLU M.
39.Ulusal Nöroloji Kongresi, Trabzon, Türkiye, 22 - 26 Ekim 2003
2003
2003173. Ulseratif kolitle ilişkili hemorajik infarkt vaka sunumu
ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZGÜR S., ÖZMENOĞLU M.
39. Ulusal Nöroloji Kongresi, Trabzon, Türkiye, 22 - 26 Ekim 2003
2003
2003174. Doğu Karadeniz bölgesindeki multipl skleroz hastalarının klinik ve demografik özellikleri
ACAR Ö., BOZ C., ALTUNAYOĞLU ÇAKMAK V., ÖZMENOĞLU M.
39. Ulusal Nöroloji Kongresi, Trabzon, Türkiye, 22 - 26 Ekim 2003
2003
2003175. Agırlık kaldırma egsersizi sonrası gelisen spinal aksesöri sinir hasarı
ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZMENOĞLU M.
39.Ulusal Nöroloji Kongresi, Antalya, Türkiye, 22 - 26 Ekim 2003, ss.369, (Tam Metin Bildiri)
2003
2003176. Dogu Karadeniz bölgesindeki multipl skleroz hastalarının klinik ve demografik özellikleri
ACAR Ö., BOZ C., ALTUNAYOĞLU ÇAKMAK V., ÖZMENOĞLU M.
39.Ulusal Nöroloji Kongresi, Antalya, Türkiye, 22 - 26 Ekim 2003, ss.440-441, (Tam Metin Bildiri)
2003
2003177. Ulseratif kolitle iliskili hemorajik infarkt vaka sunumu
ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZGÜR S., ÖZMENOĞLU M.
39.Ulusal Nöroloji Kongresi, Antalya, Türkiye, 22 - 26 Ekim 2003, ss.336-337, (Tam Metin Bildiri)
2003
2003178. The efficacy and safety of dipyrone (NOVALGIN) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multicenter pilot study
Tulunay F., Ergun H., Gulmez S., Ozbenli T., Ozmenoglu M., Boz C., et al.
11th Congress of the International-Headache-Society, Rome, İtalya, 12 - 16 Eylül 2003, cilt.23, ss.578, (Özet Bildiri)
2003
2003179. Lokal soğuk uygulamasının sempatetik deri yanıtı toparlanma eğrisine etkisi
BOZ C., ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S., ÖZMENOĞLU M.
20. Ulusal Klinik Nörofizyoloji EEG-EMG Kongresi, Gaziantep, Türkiye, 27 - 31 Mayıs 2003, (Tam Metin Bildiri)
2003
2003180. Lokal soguk uygulamasının sempatetik deri yanıtı toparlanma egrisine etkisi
BOZ C., ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S., ÖZMENOĞLU M.
20. Ulusal Klinik Nörofizyoloji EEG-EMG Kongresi, Gaziantep, Türkiye, 27 - 31 Mayıs 2003, ss.29, (Tam Metin Bildiri)
2002
2002181. Mermer beyin hastalığı serebral kalsifikasyon renal tübüler asidoz osteopetrosis
BOZ C., ALTUNAYOĞLU ÇAKMAK V., KAYNAR R. K., ALİOĞLU Z., VELİOĞLU S., ÖZMENOĞLU M.
38. Ulusal Nöroloji Kongresi, Trabzon, Türkiye, 19 - 23 Ekim 2002
2002
2002182. Mermer beyin hastalıgı serebral kalsifikasyon, renal tübüler asidoz, osteopetrosis.
BOZ C., ALTUNAYOĞLU ÇAKMAK V., KAYNAR R. K., ALİOĞLU Z., VELİOĞLU S., ÖZMENOĞLU M.
38. Ulusal Nöroloji Kongresi,, Antalya, Türkiye, 19 - 23 Ekim 2002, ss.107, (Tam Metin Bildiri)
2002
2002183. El ve vücut ölçeklerinin karpal tünel sendromu ile iliskisi
BOZ C., ALTUNAYOĞLU ÇAKMAK V., VELİOĞLU S., ÖZMENOĞLU M., TAN M.
19. Ulusal Klinik Nörofizyoloji EEG-EMG Kongresi, Trabzon, Türkiye, 08 Haziran 2002 - 13 Haziran 2003, ss.206, (Tam Metin Bildiri)
2002
2002184. Karpal tünel sendromunda ısının sinir ileti parametrelerine etkisi
BOZ C., ALTUNAYOĞLU ÇAKMAK V., ÖZMENOĞLU M., TAN M.
19. Ulusal Klinik Nörofizyoloji EEG-EMG Kongresi, Trabzon, Türkiye, 8 - 13 Haziran 2002, ss.205, (Tam Metin Bildiri)
Kitaplar
2020
20203. Multipl Skleroz Tedavi Geçişlerinde Uygulamalar
AKÇALI A., AKSOY D., Altıntaş A., ALTUN Y., ALTUNRENDE B., ARDUÇ AKÇAY A., et al.
Türkiye Klinikleri Nöroloji Özel Konular-Multipl Skleroz, Duman Taşkın, Editör, Türkiye Klinikleri, ss.88-93, 2020
2018
20184. Soru ve Yanıtlarla Multipl Skleroz
TERZİ M., BOZ C., BÖLÜKBAŞI O.
No-bel Matbaacılık San.Tic.Ltd. Şti., 2018
2016
20165. Soru ve Yanıtlar ile Multipl Skleroz
BOZ C., TERZİ M., BÖLÜKBAŞI O.
Ömür matbaacılık, 2016
Diğer Yayınlar
2004
20041. Local cold effect on the excitability recovery curve of the sympathetic skin response
BOZ C., ÖZMENOĞLU M., ALİOĞLU Z., VELİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S.
Diğer, ss.497-501, 2004
Desteklenen Projeler
2025 - 2027
2025 - 2027MS AI-NET: Multipl Skleroz için Yapay Zeka Tabanlı Karar DestekSistemi
TÜSEB B Grubu AR-GE Projesi
Kurt B. (Yürütücü), Eyüboğlu İ., Boz C., Özdemir S., Albayrak M.
2016 - 2017
2016 - 2017Bell Paralizili Hastalarda Akupunktur Tedavisi Öncesi ve Sonrası Elektrofizyolojik ve Morfometrik Ölçümlerin Değerlendirilmesi
Yükseköğretim Kurumları Destekli Proje , BAP Doktora
KALAYCIOĞLU A. (Yürütücü), ERTEMOĞLU ÖKSÜZ C., BOZ C., KALKIŞIM Ş. N., UZUN Ö., YILDIRIM A.
Atıflar
Toplam Atıf Sayısı (WOS): 4870
h-indeksi (WOS): 34
Jüri Üyelikleri
Ekim-2015
Ekim 2015